

# NEW APPROACHES TO MENTAL ILLNESS

## IN THE ERA OF THE NATIONAL BRAIN INITIATIVE



ASCP ANNUAL MEETING  
June 16 - 19, 2014  
HOLLYWOOD, FL



ASCP

AMERICAN SOCIETY OF  
CLINICAL PSYCHOPHARMACOLOGY

[www.ASCPMeeting.org](http://www.ASCPMeeting.org)



**ASCP**  
AMERICAN SOCIETY OF  
CLINICAL PSYCHOPHARMACOLOGY

Dear Colleagues:

On behalf of the American Society of Clinical Psychopharmacology (ASCP), we are very pleased to welcome you to this year's "ASCP Annual Meeting." In 2010, several decisions were made that allowed ASCP to reinvent NCDEU as "the New NCDEU." Over the last three years "the New NCDEU" has been quite successful. Moving forward in 2014, the ASCP Board and the ASCP/NCDEU Steering Committee have decided to rename the meeting the "ASCP Annual Meeting."

The ASCP is proud to sponsor the meeting, now in its 54th year.

Psychopharmacology is an exciting field undergoing dramatic changes, with the identification of new molecular targets and the development of novel compounds. Our Society keeps its members abreast of such innovations. Our annual meeting serves as the vehicle for the dissemination of cutting edge psychopharmacology research. We will continue to develop ways for members to feel more connected with our Society and to include more clinically focused symposia.

Another major goal for ASCP is to increase its visibility to those interested in the practice of psychopharmacology, thereby helping our membership grow. With over 1,000 annual attendees, the meeting has also become a key opportunity for networking, planning and to develop the next generation of clinical researchers.

A very special thank you to the members of the ASCP/NCDEU Steering and ASCP Program Committees for their critical role in the success of the meeting. We are all looking forward to an exciting and highly informative ASCP Annual Meeting.

Maurizio Fava, M.D.  
President

American Society of Clinical Psychopharmacology

## **Welcome to the ASCP Annual Meeting**

On behalf of the ASCP Annual Meeting Steering and Program Committees, we are delighted to welcome you to the ASCP Annual Meeting. Though the name of the meeting has changed, the ASCP is committed to continue to build on the past success of NCDEU with program innovation while preserving the rich history of this meeting. Below are some of the highlights of the 2014 meeting.

The annual meeting brings together academic investigators, industry scientists, U.S. and international regulators, National Institutes of Health (NIH) and other professionals who work in drug development and clinical trials.

- **2014 Program Highlights**

- Monday, June 16
  - Conference Opening
  - Pharma Pipeline: 10 presentations of Phase 1 and Phase 2 developments.
- Tuesday, June 17
  - 15<sup>th</sup> Annual Fun Run/Walk
  - Regulatory Plenary: *FDA Science Initiatives: A Brief Update*
  - ASCP Lifetime Awardee Talk
  - Poster Session I
  - ASCP Reception
- Wednesday, June 18
  - Keynote Plenary Session: *New Approaches to Mental Illness in the Era of the National Brain Initiative*
  - NIH Institute Directors Plenary
  - Poster Session II
  - Updates Session – *The Latest on Treatment of Mood, OCD-spectrum, and Binge Eating Disorders*
  - Workshops
- Thursday, June 19
  - Regulatory Wrap-Up Plenary with the FDA
- Throughout the meeting
  - NIMH, NIDA, NCCAM, and NIAAA panels
- The New Investigator Program
  - A closed workshop for 20 New Investigators and informal breakfast sessions
- Workshops: 2 hour intensive interactive sessions focused on problems and solutions
  - Tuesday and Wednesday Afternoons
- **\*Clinical Track\*** – sessions focused on topics of immediate clinical relevance

- **Organization**

- The meeting is sponsored by the American Society for Clinical Psychopharmacology (ASCP).
  - The Steering Committee organizes the meeting.
  - The Program Committee evaluates submitted proposals and develops program innovations.
- NIH collaborations:
  - NIMH - National Institute of Mental Health
  - NIDA - National Institute of Drug Abuse
  - NIAAA - National Institute on Alcohol Abuse and Alcoholism
  - NCCAM - National Center for Complementary and Alternative Medicine
  - CSR – Center for Scientific Review
  - NCATS - National Center for Advancing Translational Sciences
- Regulatory agency collaborations:
  - Food and Drug Administration (FDA)
- Parthenon Management Group organizes the ASCP Annual Meeting.

- **And remember**

- The Opening Reception is Tuesday, June 17<sup>th</sup> from 7:00 pm – 8:00 pm.
- The Fun Run/Walk is Tuesday, June 17<sup>th</sup> at 6:45 am.

The ASCP Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.


Best Regards,



Husseini Manji, M.D., FRCPC  
Steering Committee Co-Chair



Carlos Zarate, M.D.  
Program Committee Co-Chair




Michael E. Thase, M.D.  
Steering Committee Co-Chair




Holly A. Swartz, M.D.  
Program Committee Co-Chair


## 2nd Floor Convention Center



## Resort, Second Floor



## Resort, Third Floor



## Future ASCP Meetings

## ASCP

- **State of the Art – Fall Psychopharmacology Update Meeting**  
**October 11-12, 2014**  
**New York, New York**
- **2015 ASCP Annual Meeting**  
**June 22-25, 2015**  
**Miami Beach, Florida**

Award Winners and Featured Speakers .....	5
Acknowledgements .....	15
Meeting Announcements .....	21
Sunday, June 15, 2014 .....	25
Monday, June 16, 2014 .....	27
Tuesday, June 17, 2014 .....	41
Wednesday, June 18, 2014 .....	53
Thursday, June 19, 2014 .....	63
Poster Session 1 .....	69
Poster Session 2 .....	81
Author Index .....	93

**DISCLOSURES FOR ALL ASCP PRESENTERS  
CAN BE VIEWED AT [WWW.ASCPMEETING.ORG](http://WWW.ASCPMEETING.ORG)**

**Recipient of the Donald Klein Lifetime Achievement Award****A. John Rush, M.D.****Duke-National University of Singapore**

Dr. Rush majored in Biochemistry at Princeton and completed his M.D. at Columbia College of Physicians and Surgeons. Following his internship in general medicine (Passavant Hospital, Northwestern University), he served in the U.S. Army before joining the Special Action Office for Drug Abuse Prevention in Washington D.C. After his psychiatric residency at the University of Pennsylvania, he became Assistant Professor at the University of Oklahoma and subsequently joined the Departments of Psychiatry

and later the Department of Clinical Sciences at the University of Texas Southwestern Medical Center at Dallas. In 2008, he became Vice Dean of Clinical Sciences and Professor at Duke-NUS (Singapore).

At Duke-NUS he founded and developed several programs designed to advance patient oriented research careers of medical, surgical and mental health, nursing and allied health practitioners including the Academic Medicine Research Institute, the Center for Quantitative Medicine, and the Medical Student III program in clinical research.

His research has focused on the development and testing of innovative treatments for mood disorders including medications, medication combinations, somatic treatments, psychotherapy, and disease management protocols (treatment algorithms). He has authored more than 600 papers and chapters and 10 books. He was Principal Investigator on the NIMH sponsored STAR\*D (Sequenced Treatment Alternatives to Relieve Depression) trial and directed the NIMH Depression Trials Network (DTN). Past awards include the Mood Disorders Research Award (American College of Psychiatrists), the Paul Hoch Award (American Psychopathological Association), the Edward J. Sachar Award (Columbia College of P & S), the Nola Maddox Falcone Prize (NARSAD), the American Psychiatric Association Award for Research in Psychiatry, and the Gold Medal Award (Society of Biological Psychiatry). He has served as President of the Society of Biological Psychiatry and Society for Psychotherapy Research. He presently provides consultation to academic centers, government and industrial organizations and entities.

**Recipient of the Paul Wender Best Paper  
in the *Journal of Clinical Psychiatry* Award**



**Sophie Grigoriadis, M.D.  
Sunnybrook Health Sciences Centre**

**Nominated for: *Antidepressant Exposure During Pregnancy and Congenital Malformations: Is There an Association? A Systematic Review and Meta-Analysis of the Best Evidence***

Sophie Grigoriadis, M.D., Ph.D., FRCPC; Emily H. VonderPorten, MPH; Lana Mamisashvili, MSW; Michael Roerecke, Ph.D.; Jürgen Rehm, Ph.D.; Cindy-Lee Dennis, Ph.D.; Gideon Koren, M.D.,

FRCPC, FACMT; Meir Steiner, M.D., Ph.D., FRCPC; Patricia Mousmanis, M.D., CCFP, FCFP; Amy Cheung, M.D., MSc, FRCPC; and Lori E. Ross, Ph.D.

Dr. Grigoriadis is the Head of the Women's Mood and Anxiety Clinic: Reproductive Transitions at Sunnybrook Health Sciences Centre and scientist at the Sunnybrook Research Institute. She was the Academic Leader of the Reproductive Life Stages Program at Women's College Hospital, Fellowship Director in the department of psychiatry at the University Health Network (UHN) and a Staff Psychiatrist at both sites including the Mood Disorders Psychopharmacology Unit at UHN until September 2011. She is an Associate Professor in the Mood and Anxiety Disorders and Women's Mental Health Programs, Department of Psychiatry, Faculty of Medicine, at the University of Toronto.

Dr. Grigoriadis completed her medical degree at McMaster University and her psychiatry residency at the University of Toronto. Prior to Medical school, she completed a MA and Ph.D. in Clinical Psychology at Queen's University, and internship in Clinical Psychology at the Toronto Hospital. Dr. Grigoriadis' clinical interests include women with depression especially during pregnancy, the postpartum period and during perimenopause. Her treatment strategies include both the use of pharmacotherapy as well as short-term psychotherapies. Current research focuses on the presentation of mood disorders in women across the lifespan, hormonal influences in the presentation and treatment of depression during the postpartum and perimenopause, and differences in the presentation and response to antidepressant medications among women of various ages. Dr. Grigoriadis is also actively involved in developing novel treatment strategies for depression. She is currently leading several studies including developing a tool to assist clinicians in making treatment decisions with their depressed perinatal patients and is developing treatment guidelines for the treatment of depression during the perimenopause. She is an author in the Canadian Guidelines for the Treatment of Depression. Her educational activities include teaching psychiatry residents, training family practice as well as psychiatry residents in Interpersonal Psychotherapy and teaching in continuing medical education programs.



## **Regulatory Plenary - FDA Science Initiatives: A Brief Update**

**Tuesday, June 17, 2014 from 8:30 am – 10:00 am**



**Ni Khin, M.D.**  
**Food and Drug Administration**

Dr. Ni Khin is Acting Division Director in Division of Good Clinical Practice Compliance, Office of Scientific Investigations, Center for Drug Evaluation and Research, FDA. She has served as Medical Team Leader in the Division of Psychiatry Products, Office of New Drugs for past 8 years. In this position, she oversaw the review of clinical protocols submitted under investigational new drug applications (INDs) for all phases of drug development. She also managed, as cross-disciplinary team leader, regulatory and clinical reviews of New Drug Applications (NDAs) for all psychiatric indications. She joined the Agency in 2001 as a Clinical Reviewer in the Division of Neuropharmacologic Drug Products. She also worked as Medical Officer and Branch Chief of Good Clinical Practice Branch 1, Division of Scientific Investigations, where she provided scientific oversight for CDER-assigned bioresearch monitoring (BIMO) activities. She conducted on-site data-audit inspections of clinical trial sites both in the US and abroad. Prior to coming to FDA, Dr. Khin was a Senior Staff Fellow in the Geriatric Psychiatry Branch at the National Institute of Mental Health.

Dr. Khin received her medical degree from the Institute of Medicine I, Rangoon, Burma (Myanmar). She completed residency training in Psychiatry at the State University of New York, Buffalo. She is board-certified in Psychiatry by the American Board of Psychiatry and Neurology. She also received a Master of Science Degree from Arizona State University. Her regulatory research interest includes trial design and methodology to improve detection of efficacy signals as well as regulatory and scientific issues regarding use of foreign data from global trials in support of NDA's.

**Celia Winchell, M.D.**  
**Food and Drug Administration**

Celia Winchell is the Medical Team Leader for Addiction Products in the FDA's Division of Anesthesia, Analgesia, and Addiction Products in the Center for Drug Evaluation and Research. Since 1995, Dr. Winchell has been providing regulatory oversight for drug development in all aspects of addiction treatment, and for academic research involving drugs of abuse. Dr. Winchell holds a bachelor's degree in psychology from Harvard University, and a medical degree from the University of Virginia. She completed residency training in psychiatry at Johns Hopkins Hospital.



**Silvana Borges, M.D.**  
**Food and Drug Administration**

Dr. Borges received her medical degree from the State University School of Medicine in Uruguay. She completed her medical residency and is board certified in Child & Adolescent Psychiatry. She joined the Department of Pharmacology and Therapeutics in the State University School of Medicine as an Assistant Professor and then became an Assistant Professor and Founding Member of the “National Center for Drug Safety” in Uruguay. She was a Scholar at the Catalan Institute of Pharmacology (Barcelona, Spain) focusing her training in drug safety and pharmacoepidemiology. She received the Merck Foundation International Fellowship in Clinical Pharmacology Award and completed a fellowship in clinical pharmacology and pharmacogenetics at Indiana University, being mentored by Dr. David Flockhart. She was the recipient of the American Society for Clinical Pharmacology and Therapeutics Presidential Trainee Award for her work on the role of CYP2D6 genetic polymorphism on tamoxifen metabolism and its interaction with antidepressants. She joined the FDA in 2007 and is currently an Acting Clinical Team Leader with the Division of Psychiatry Products, Office of New Drugs, Center for Drug Evaluation and Research.

**Plenary: *New Approaches to Mental Illness in the Era of the National Brain Initiative***

**Wednesday, June 18, 2014 from 8:15 am - 9:45 am**



**Hussein Manji, M.D., FRCP**  
**Johnson & Johnson Pharmaceutical Research & Development**

Hussein K. Manji, M.D., FRCP, is Global Therapeutic Head for Neuroscience at Janssen Research & Development, LLC, a division of Johnson & Johnson. Previously, he was Chief, Laboratory of Molecular Pathophysiology & Experimental Therapeutics, NIH, and Director of the NIH Mood and Anxiety Disorders Program. Dr. Manji received his B.S. and M.D. from the University of British Columbia. He completed fellowship training at the NIMH and completed additional training in cellular and molecular biology. His research has focused on investigation of disease-and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity. His work has led to investigation of novel therapeutics for patients with refractory neuropsychiatric illnesses. Dr. Manji has also been involved in medical and postgraduate neuroscience education and has published extensively on the molecular and cellular neurobiology of neuropsychiatric disorders and the development of novel therapeutics. Dr. Manji has received numerous distinguished scientific and academic awards, including the NIMH Director's Career Award for Significant Scientific Achievement, and was inducted into the U.S. Institute of Medicine of the National Academies in 2008. He has served as Chair of the American College of Neuropsychopharmacology, is a Counselor to the Society of Biological Psychiatry and serves on a variety of editorial boards of scholarly journals. He holds voluntary leadership positions in many organizations devoted to advancement of neuroscience and advocacy for people with neuropsychiatric illnesses. He has been a member of the Howard Hughes Medical Institute and NIH Research Scholars Program Advisory Committee.



**Thomas Insel, M.D.**  
**National Institute of Mental Health**

Thomas R. Insel, M.D., is Director of the National Institute of Mental Health (NIMH), the component of the National Institutes of Health charged with generating knowledge to understand, treat and prevent mental disorders. His tenure at NIMH has been distinguished by groundbreaking findings on the genetics and neurobiology of mental disorders as well as efforts to transform the diagnosis and treatment of serious mental illnesses. In addition

to his leadership of the NIMH, Dr. Insel has served as Chair of the Interagency Autism Coordinating Committee (Since 2002), co-chair of the NIH Blueprint for Neuroscience Research (since 2004), and Acting Director of the National Center for Advancing Translational Science (2011-2012). Currently, Dr. Insel is on the leaders for the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) effort, a Presidential initiative focused on developing new tools for understanding the brain.

Prior to his appointment as NIMH Director in the Fall 2002, Dr. Insel was Professor of Psychiatry at Emory University. There, he was founding director of the Center for Behavioral Neuroscience and director of an NIH-funded Center for Autism Research. From 1994 to 1999, he was Director of the Yerkes Regional Primate Research Center in Atlanta. While at Emory, Dr. Insel continued the line of research he had initiated at NIMH, studying the neurobiology of complex social behaviors. He has published over 280 scientific articles and four books, including the *Neurobiology of Parental Care* (with Michael Numan) in 2003.

Dr. Insel is a member of the Institute of Medicine, a fellow of the American College of Neuropsychopharmacology, and is a recipient of several awards, including the Outstanding Service Award from the U.S. Public Health Service and the 2010 La Foundation IPSEN Neuronal Plasticity Prize. Dr. Insel graduated from the combined B.A.-M.D. program at Boston University in 1974. He did his internship at Berkshire Medical Center, Pittsfield, Massachusetts, and his residency at the Langley Porter Neuropsychiatric Institute at the University of California, San Francisco.



**Patrick Kennedy**  
**Former US Representative and Mental Health Activist**

Patrick J. Kennedy became the youngest member of the Kennedy family to hold elected office when, in 1988, he won election to the Rhode Island House of Representatives at age 21. Since then, Kennedy went on to serve 16 years in the United States House of Representatives, representing Rhode Island's first congressional district from 1994 to 2011. While in office, he distinguished himself as a leader on issues of healthcare, sciences, veterans, technology, civil rights, and mental health.

As a founding member of the 21st Century Healthcare Caucus; the Addiction, Treatment and Recovery Caucus; and the Down Syndrome Caucus, Kennedy has been a tireless advocate for access to health and advancements in medical research.

Throughout his career, Kennedy has been a vocal advocate for healthcare reform. He was the author and chief House sponsor of the Wellstone-Domenici Mental Health Parity and Addiction Equity Act of 2008, an act that expanded access to mental health services to over 100 million Americans. He has also authored and co-sponsored dozens of bills to increase the understanding and treatment of neurological and psychiatric disorders, including the National Neurotechnology Initiative Act, the Genomics and Personalized Medicine Act, the Combat PTSD Act, and the Alzheimer's Treatment and Caregiver Support Act.

Since leaving office in 2011, Patrick J. Kennedy has been devoting his efforts to promoting research in neuroscience. He co-founded One Mind for Research, a nonprofit organization, the mission of which is to be the leader in brain research in order to eliminate stigma, transform policy, and allocate resources that will help both our understanding and treatment of brain diseases. In addition to One Mind for Research, Kennedy is also an active board member of Best Buddies, Research America, and the Edward M. Kennedy Institute for the United States Senate.

The champion of mental health in Congress who believes that "the brain is the last medical frontier." Patrick J. Kennedy is a sought-after speaker on mental health, healthcare, and many other related issues. He was invited by House Minority Leader Nancy Pelosi to address the Democratic Caucus on mental health and will launch the Kennedy Forum on Community Mental Health. In 2013, he spoke at the National Institute of Mental Health Alliance for Research Progress, the US/Canada Forum on Mental Health and Productivity, and the Mental Health America Conference.

## **Institute Directors Plenary**

**Wednesday, June 18, 2014 from 10:00 am – 12:00 pm**

**Thomas Insel, M.D.**

**National Institute of Mental Health**

*See previous bio*



**Phillip Skolnick, Ph.D., D.Sc. (hon.)**

**National Institute on Drug Abuse**

Phil Skolnick is the Director, Division of Pharmacotherapies and Medical Consequences of Drug Abuse at the National Institute on Drug Abuse, NIH. Dr. Skolnick served as Chief Scientific Officer (2001-2009) and President (2007-2009) of DOV Pharmaceutical, Inc. He was also Research Professor of Psychiatry (2001-2009) and a member of the Center of Excellence on Drug Addiction at New York University-Langone Medical Center. Dr. Skolnick was a

Lilly Research Fellow (Neuroscience) at Lilly Research Laboratories (1997-2000). Prior to this, he was a Senior Investigator and Chief, Laboratory of Neuroscience, at the NIH intramural research program (1986-1997). Dr. Skolnick has also served as a Research Professor of Psychiatry at the Uniformed Services University of the Health Sciences, Adjunct Professor of Anesthesiology at Johns Hopkins University, and Adjunct Professor of Pharmacology and Toxicology at Indiana University School of Medicine. He received a Ph.D. from the Department of Pharmacology, George Washington University School of Medicine (1972), and served as a Staff Fellow and Senior Staff Fellow at the NIH under Dr. John W. Daly (1972-1977).

His awards and honors include the Experimental Therapeutics Prize from the American Society for Pharmacology and Experimental Therapeutics, an Anna Monika Prize, and the A.E. Bennett Award in Biological Psychiatry. He has twice been awarded the Doctor of Science, honoris causa. Dr. Skolnick has co-authored more than 500 articles and currently serves on the editorial advisory board of seven journals. He is currently an editor of Current Protocols in Neuroscience, and has also edited six books. The Institute of Scientific Information (ISI) has acknowledged his contributions by naming him to the elite group of "Highly Cited" authors.

**Kenneth Warren, Ph.D., D.Sc.****National Institute on Alcohol Abuse and Alcoholism**

Kenneth R. Warren, Ph.D., a nationally-recognized expert on alcohol and pregnancy, and a long-time senior administrator at the National Institute on Alcohol Abuse and Alcoholism (NIAAA) became Acting Director of NIAAA on November 1, 2008, following the retirement of Ting-Kai Li, M.D. on October 31, 2008. Dr. Li had served as NIAAA Director from September 2002 through October 2008. Dr. Warren was named as the NIAAA Deputy Director in February 2008. He held numerous positions in NIAAA since joining the Institute in 1976.

A graduate of the City College of New York, Dr. Warren earned his doctorate degree in Biochemistry from Michigan State University in 1970. He subsequently undertook postdoctoral positions at the University of California, Los Angeles and at University of Michigan Mental Health Research Institute before joining the Federal government in a research position at the Walter Reed Army Institute of Research in 1974.

Dr. Warren has maintained an active interest in all areas of alcohol and health and in past years often served as the editor of the triennial Reports to Congress on Alcohol and Health. He has been particularly active in research on the effects of alcohol use during pregnancy, including fetal alcohol syndrome (FAS) and fetal alcohol spectrum disorders (FASD). Dr. Warren initiated NIAAA's research program on FAS over 30 years ago. He currently chairs the government-wide Interagency Coordinating Committee on FAS.

Dr. Warren has received numerous honors, including a superior service award from the Public Health Service in 1982 for his work in development of the first Surgeon General's Advisory on FAS. In 2007, the National Organization on Fetal Alcohol Syndrome (NOFAS) honored Dr. Warren by placing his name into their Tom and Linda Daschle FASD Hall of Fame, followed by the receipt of the NOFAS Excellence Award in 2008.

**Christopher P. Austin, M.D.****National Center for Advancing Translational Sciences**

In September 2012, NIH Director Francis S. Collins announced the appointment of Christopher P. Austin, M.D., as director of the National Center for Advancing Translational Sciences (NCATS). Austin succeeded former acting director of NCATS and current director of the National Institute of Mental Health Thomas R. Insel, M.D.

Austin, who served as director of the NCATS Division of Pre-clinical Innovation since the creation of the Center in December 2011, is leading NCATS in its mission to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Currently, many costly, time-consuming bottlenecks exist in the translational pipeline. Austin is applying his experiences in nearly every stage of the research pipeline to build on the Center's momentum in finding innovative ways to reduce, remove or bypass these bottlenecks and speed the delivery of new drugs, diagnostics and medical devices to patients.

After working at Merck on genome-based discovery of novel targets and drugs, Austin began his NIH career in 2002 as the Senior Advisor to the Director for translational research at the National Human Genome Research Institute, where he initiated the Knockout Mouse Project and the Molecular Libraries Roadmap Initiative. Other NIH roles have included serving as Director of the Therapeutics for Rare and Neglected Diseases program as well as the NIH Chemical Genomics Center and as Scientific Director of the NIH Center for Translational Therapeutics.

Austin earned a medical degree from Harvard Medical School and an undergraduate degree in biology from Princeton University. He completed clinical training in internal medicine and neurology at Massachusetts General Hospital as well as a fellowship in genetics at Harvard.



**Richard Nakamura, M.D.**  
**Center for Scientific Review**

Dr. Richard K. Nakamura is the Director of the Center for Scientific Review. In that capacity, he leads the review of grant applications of the National Institutes of Health. Dr. Nakamura received his Bachelor of Arts in Psychology from Earlham College and his Ph.D. in Psychology from State University of New York (Stony Brook, NY). He was with the National Institute of Mental Health from 1976 to 2011. In 2001, he received the NIH-Asian/Pacific American Organization (APAO) Outstanding Achievement Award for Administrative Work.

In 2002, Dr. Nakamura was elected by the American Association for the Advancement of Science (AAAS) to the status of AAAS Fellow. Also in 2002, Dr. Nakamura was awarded the Presidential Rank Award for outstanding leadership. In 2004 and 2005, respectively, he received leadership awards from the Federation of Behavioral Psychological and Cognitive Sciences, and from the International Society for Behavioral Neuroscience. In 2009, he was awarded the NIH Director's Award for Outstanding Administration.



**Josephine Briggs, M.D.**  
**National Center for Complementary and Alternative Medicine**

An accomplished researcher and physician, Dr. Briggs received her A.B. in biology from Harvard-Radcliffe College and her M.D. from Harvard Medical School. Previous to her appointment at NCCAM, she was director of the Division of Kidney, Urologic, and Hematologic Diseases at the NIH National Institute of Diabetes and Digestive and Kidney Diseases. In 2006, Dr. Briggs became Senior Scientific Officer

at the Howard Hughes Medical Institute. In January 2008, she returned to NIH as the NCCAM Director.



**Regulatory Wrap-Up****Thursday, June 19, 2014 from 10:15 am – 11:45 am****Ni Khin, M.D.****Food and Drug Administration***See previous bio***Celia Winchell, M.D.****Food and Drug Administration***See previous bio***Silvana Borges, M.D.****Food and Drug Administration***See previous bio***Phillip Kronstein, M.D.****Food and Drug Administration, CDER**

Phillip Kronstein, M.D., is a Senior Medical Officer in the Division of Psychiatry Products (DPP) at the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER). In this position, Dr. Kronstein manages clinical reviews of Investigational New Drugs (INDs) and New Drug Applications (NDAs). Prior to joining the FDA in January 2008, he was a Clinical Research Fellow in the Experimental Therapeutics and

Pathophysiology Branch at the National Institute of Mental Health, where he conducted trials in treatment-resistant depression and bipolar disorder. He received a Bachelor's of Science in Chemistry from the University of Chicago in 1995 and a Doctor of Medicine from Tufts University School of Medicine in 2001. He completed his residency training in Psychiatry at the Johns Hopkins Hospital in June 2005. In addition to his review responsibilities at the FDA, Dr. Kronstein has been involved in regulatory research, looking at sexual dysfunction with antidepressants. He is also the Division Data Standards Lead for DPP as CDER, as part of a larger FDA initiative, continues to develop and implement standards to represent study data submitted in support of regulatory applications.



## Steering Committee Chairs



**Husseini Manji, M.D., FRCPC**



**Michael E. Thase, M.D.**

## Program Chairs



**Carlos Zarate, M.D.**




**Holly A. Swartz, M.D.**

## New Investigator Award Program Chairs



**Lauren D. Hill, Ph.D.**



**Mark H. Rapaport, M.D.**

## **Steering Committee Members**

Karl Broich, M.D.  
Federal Institute of Drugs and Medical Devices

- ★ Lori Davis, M.D.  
Tuscaloosa VA Medical Center

Maurizio Fava, M.D.  
The Massachusetts General Hospital (ASCP Board Member)

Marlene Freeman, M.D.  
Harvard Medical School (ASCP Board Member)

Bruce Kinon, M.D.  
Eli Lilly & Company

James H. Kocsis, M.D.  
Weill-Cornell Medical College

David J. Kupfer, M.D.  
University of Pittsburgh School of Medicine

Thomas P. Laughren, M.D.  
Food and Drug Administration

Raye Litten, Ph.D.  
National Institute of Alcohol Abuse and Alcoholism

- ★ Anil K. Malhotra, M.D.  
Hofstra NS-LIJ School of Medicine  
The Zucker Hillside Hospital

Husseini K. Manji, M.D., FRCPC  
Johnson & Johnson Pharmaceutical Research & Development

Steve Marder, M.D.  
University of California Los Angeles

David Michelson, M.D.  
Merck & Company, Inc.

Andrew A. Nierenberg, M.D.  
Massachusetts General Hospital

William Z. Potter, M.D., Ph.D.  
Foundation for the National Institute of Health

Stephanie O'Malley, Ph.D.  
Yale University School of Medicine

★ **New Investigator Alumni** ▲ **Representing ASCP CME Committee**

## **Steering Committee Members (continued)**

- ▲ Mark H. Rapaport, M.D.  
Emory University School of Medicine (ASCP Board Member)  
  
Bob A. Rappaport, M.D.  
Center for Drug Evaluation and Research, FDA  
  
Steve Romano, M.D.  
Pfizer, Inc.  
  
Nina R. Schooler, Ph.D.  
State University of New York, Downstate Medical Center  
  
Philip Skolnick, Ph.D., D.Sc.  
National Institute on Drug Abuse  
  
Michael Thase, M.D.  
University of Pennsylvania School of Medicine (ASCP Board Member)  
  
Ben Vitiello, M.D.  
National Institute of Mental Health
- ★ Carlos A. Zarate, M.D.  
National Institute of Mental Health

## **Program Committee**

- Leslie Citrome, M.D., M.P.H.  
New York Medical College (ASCP Board Member)
- ★ Christoph U. Correll, M.D.  
The Zucker Hillside Hospital (ASCP Board Member)  
  
Thilo Deckersbach, Ph.D.  
Massachusetts General Hospital  
  
Bryan L. Dirks, M.D.  
Shire Pharmaceuticals  
  
Eden Evins, M.D.  
Harvard Medical School
- ★ Tiffany R. Farchione, M.D.  
Food and Drug Administration  
  
Maurizio Fava, M.D.  
Massachusetts General Hospital (ASCP Board Member)  
  
Bradley Gaynes, M.D.  
University of North Carolina

★ **New Investigator Alumni** ▲ **Representing ASCP CME Committee**

## **Program Committee (continued)**

John Greist, M.D.  
Healthcare Technology Systems, Inc.

Richard Keefe, Ph.D.  
Duke University Medical Center

Terence Ketter, M.D.  
Stanford University School of Medicine

Helena Kraemer, Ph.D.  
Stanford University

Charlotte Kremer, M.D.  
Astellas Pharmaceuticals

David J. Kupfer, M.D.  
University of Pittsburgh School of Medicine

Thomas P. Laughren, M.D.  
Food and Drug Administration

★ Anil Malhotra, M.D.  
Hofstra NS-LIJ School of Medicine, The Zucker Hillside Hospital

Stephen Marder, M.D.  
Semel Institute, UCLA

▲ Craig Nelson, M.D.  
University of California San Francisco

★ Katharine Phillips, M.D.  
Rhode Island Hospital/Brown University

Steve Romano, M.D.  
Pfizer, Inc.

Jerrold Rosenbaum, M.D.  
Massachusetts General Hospital

Neil Ryan, M.D.  
University of Pittsburgh School of Medicine

Martha Sajatovic, M.D.  
University Hospitals Case Medical Center

Bruce Saltz, M.D., P.A.  
Mental Health Advocates, Inc.

Richard Shelton, M.D.  
University of Alabama at Birmingham

★ **New Investigator Alumni** ▲ **Representing ASCP CME Committee**

## **Program Committee (continued)**

- ★ Holly A. Swartz, M.D.  
University of Pittsburgh School of Medicine  
Benedetto Vitiello, M.D.  
National Institute of Mental Health  
Karen Wagner, M.D.  
University of Texas, Galveston (ASCP Board Member)
- ★ Janet Williams, D.S.W.  
MedAvante
- ★ Kimberly Yonkers, M.D.  
Yale School of Medicine
- ★ Carlos A. Zarate, M.D.  
National Institute of Mental Health

## **New Investigator Award Committee**

- ★ Christoph U. Correll, M.D.  
The Zucker Hillside Hospital
- ★ Lori Davis, M.D.  
Tuscaloosa VA Medical Center
- ★ Tiffany Farchione, M.D.  
Food and Drug Administration  
Lindsey Grandison, Ph.D.  
National Institute on Alcohol Abuse and Alcoholism  
Lauren D. Hill, Ph.D.  
National Institute of Mental Health  
Bruce Kinon, M.D.  
Eli Lilly & Company  
Ivan Montoya, M.D., MPH  
National Institute on Drug Abuse
- ★ Katharine Phillips, M.D.  
Rhode Island Hospital/Brown University
- ▲ Mark H. Rapaport, M.D.  
Emory University School of Medicine (ASCP Board Member)  
Nina R. Schooler, Ph.D.  
State University of New York, Downstate Medical Center
- ★ Holly A. Swartz, M.D.  
University of Pittsburgh School of Medicine

★ New Investigator Alumni ▲ Representing ASCP CME Committee

## **ASCP Officers and Board**

- Maurizio Fava, M.D. – ASCP President  
Massachusetts General Hospital
- ▲ Mark H. Rapaport, M.D. – ASCP Treasurer  
Emory University School of Medicine
- Leslie Citrome, M.D., M.P.H.  
New York Medical College
- ★ Christoph U. Correll, M.D.  
The Zucker Hillside Hospital
- ★ Kristina Deligiannidis, M.D.  
University of Massachusetts Medical School
- Marlene Freeman, M.D.  
Massachusetts General Hospital
- Alan Gelenberg, M.D.  
Penn State University
- Ira Glick, M.D.  
Stanford University School of Medicine
- ▲ Joseph Goldberg, M.D.  
Mount Sinai School of Medicine
- John Kane, M.D.  
The Zucker Hillside Hospital
- Arif Khan, M.D.  
Duke University School of Medicine
- John Newcomer, M.D.  
Leonard M. Miller School of Medicine, University of Miami
- Michael Thase, M.D.  
University of Pennsylvania
- Karen Wagner, M.D., Ph.D.  
University of Texas Medical Branch
- Sidney Zisook, M.D.  
University of California, San Diego

★ New Investigator Alumni ▲ Representing ASCP CME Committee

## **Meeting Services**

### **Registration Desk Hours:**

Sunday	10:00 am – 5:00 pm
Monday	7:30 am – 6:30 pm
Tuesday	7:30 am – 6:45 pm
Wednesday	7:30 am – 6:00 pm
Thursday	7:30 am – 12:00 pm

\*The registration/meeting information desk is located at the main entrance of the Grand Ballroom.

**The Computer Center is open on the below dates and times for attendees to briefly check emails. The Computer Center is located in the Foyer of Diplomat 1-2. Hours:**

Sunday	12:00 pm – 5:00 pm
Monday	8:00 am – 6:00 pm
Tuesday – Wednesday	7:30 am – 6:30 pm
Thursday	7:30 am – 12:00 pm

**The ASCP Speaker Ready Room is open on the below dates and times for presenters to upload slides. The meeting organizers ask that all speakers upload their slides 24 hours prior to their scheduled presentation time.**

**The Speaker Ready Room is located in Diplomat 3. Hours:**

Sunday	12:00 pm – 5:00 pm
Monday	8:00 am – 6:00 pm
Tuesday – Wednesday	7:30 am – 6:30 pm
Thursday	7:30 am – 12:00 pm

**Americans with Disabilities Act** - It is the policy of ASCP not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3085 or send an email to [info@ascpp.org](mailto:info@ascpp.org).

**Job Announcements** may be posted on a message board at the ASCP registration desk.

**Discounts** – All ASCP Annual Meeting attendees who booked their room at the Westin Diplomat through the ASCP meeting website will have the following resort amenities.

- Access to Standard high-speed internet in the guest rooms for \$6 per day
- Fitness Center admittance
- Daily newspaper
- In-room coffee and tea

# ASCP | Meeting Announcements

## Continuing Education Credits

Disclosures are available for all ASCP Annual Meeting presenters online at [www.ASCPMeeting.org](http://www.ASCPMeeting.org).

**Continuing Education Credits** are available for physicians, pharmacists, psychologists and social workers. Applications for credit must be completed online with the meeting evaluation survey. The survey may be completed in the ASCP Computer Center in the Foyer of Diplomat 1-2 or after the conference at [www.ASCPMeeting.org](http://www.ASCPMeeting.org). ***Surveys for continuing education credit must be submitted no later than July 18, 2014.*** There is a \$40.00 administrative fee for CME/CE applications. It is the policy of the ASCP to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

### Physicians



**ASCP**  
AMERICAN SOCIETY OF  
CLINICAL PSYCHOPHARMACOLOGY

The American Society for Clinical Psychopharmacology (ASCP) designates this live meeting for a maximum of 21.5 *AMA PRA*

*Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Pharmacists



USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 21.5 contact hours. Universal program number is as follows: 0230-9999-14-0130-L01-P.

To receive continuing education credit, a pharmacist must attend the accredited sessions, actively participate in questions and answers and must return the program evaluation instrument. In order to receive full credit, registrants must arrive no later than 10 minutes after the start of the meeting and must attend the entire meeting.



## Psychologists



USF Health is approved by the American Psychological Association to sponsor continuing education for psychologists. USF Health maintains responsibility for this program and its content. This activity has been approved for 21.5 CE credits. Full attendance of the live activity is required. Partial credit will not be awarded.

## Social Workers



USF Health is an approved provider (BAP #433 – exp. 3/31/15) of continuing education credits for clinical social work, marriage and family therapy, and mental health counseling. This program has been reviewed and approved for 25.8 credit hours, 50-minute contact hours.

**All participants who request continuing education credits by July 18, 2014, should expect to receive their statement of credits via email in late August.**

**The Meeting Evaluation Survey** will be available at [www.ASCPMeeting.org](http://www.ASCPMeeting.org). We encourage all registrants to complete the evaluation. Attendees requesting CME or CE credits must complete the survey in order to obtain credits. There is a \$40.00 administrative fee for CME/CE applications. Your candid input on the 2014 meeting is appreciated as we strive to improve the meeting each year.

**ASCP Meeting Support** – The 2014 ASCP Annual Meeting received support from Otsuka Pharmaceuticals, NA for support of the New Investigator Program.

## **2015 ASCP Annual Meeting**

The 2015 ASCP Annual Meeting will take place June 22-25, 2015 at the Loews Miami Beach Hotel in Miami, Florida. Details regarding abstract submission for the 2015 Meeting will be released in September, 2014.

[illegible]

8:30am – 4:30pm

## **New Investigator Workshop (Invitation Only)**

Regency 1

**Co-Chairs:** Mark H. Rapaport, M.D., Emory University School of Medicine  
Lauren D. Hill, Ph.D., National Institute of Mental Health

The ASCP Annual Meeting offers a special program for New Investigators in an effort to promote the education and training of junior investigators in psychopharmacology. Established investigators were asked to nominate individuals who may be interested in a research career in psychopharmacology for this special program. These nominees submitted an abstract describing their current research or area of research interest, a letter of recommendation from their chair or mentor, a career statement and a curriculum vitae. The selection of awardees was based upon the scientific merit of the abstract, the level of training of the nominee and a committee of internal and external reviewers' assessment of the relative value of the specialized program to each applicant at this time in his/her career. The awardees will participate in this special educational workshop and present their posters during the scheduled poster sessions. In addition, they will receive a travel expense award and a certificate acknowledging their participation in the program at an award ceremony on Monday evening, June 16, 2014. This year's 20 New Investigator awardees are indicated with a ribbon in the poster section of this program.

### **Faculty**

Mark Bunker, Pharm.D. Cyberonics, Inc.	Katharine Phillips, M.D. Rhode Island Hospital/Brown University
Christoph U. Correll, M.D. The Zucker Hillside Hospital	A. John Rush, M.D. Duke-National University of Singapore
Lori Davis, M.D. Tuscaloosa VA Medical Center	Nina R. Schooler, Ph.D. State University of New York, Downstate Medical Center
Lindsey Grandison, Ph.D. National Institute on Alcohol Abuse and Alcoholism	Holly Swartz, M.D. University of Pittsburgh School of Medicine
Lauren Hill, Ph.D. – Chair National Institute of Mental Health	Tiffany Farchione, M.D. Food and Drug Administration

### **Special thanks to the ASCP New Investigator Program supporters:**

- Otsuka Pharmaceuticals, Inc.
- Pharmaceutical Product Development (PPD)

## 2014 New Investigator Awardees

**Eric Achytes, M.D., M.S.**

Michigan State University College of  
Human Medicine

**Ana Andreazza, Ph.D.**

University of Toronto, Departments of  
Pharmacology and Psychiatry

**Shinichiro Nakajima, M.D., Ph.D.**

Centre for Addiction and Mental Health

**Chaya Bhuvaneswaran, M.D., MPH**

Department of Psychiatry, University of  
Massachusetts-Worcester

**Kyle Burghardt, Pharm.D.**

University of Michigan College of  
Pharmacy

**Joan Camprodon, M.D., Ph.D., MPH**

Massachusetts General Hospital,  
Harvard Medical School

**Michael Davis, M.D., Ph.D.**

VA Greater Los Angeles; University of  
California Los Angeles

**Stephanie Duhoux, Ph.D.**

Icahn School of Medicine at Mount  
Sinai

**Jennifer Felger, Ph.D.**

Emory University School of Medicine

**Philip Gerretsen, M.D., MSW**

Centre for Addiction and Mental Health

**Aaron Koenig, M.D.**

Western Psychiatric Institute & Clinic

**Kamilla Miskowiak, Ph.D.**

Psychiatric Center Copenhagen,  
Copenhagen University Hospital

**Mark Niciu, M.D., Ph.D.**

National Institutes of Health (NIH)/  
National Institute of Mental Health  
(NIMH)

**Hidehiro Oshibuchi, M.D., Ph.D.**

Department of Psychiatry, University of  
California, San Francisco

**M. Mercedes Perez-Rodriguez, M.D.,  
Ph.D.**

Icahn School of Medicine at Mount  
Sinai and MIRECC at James J Peters  
VAMC

**Donna Roybal, M.D.**

University of Texas Health Sciences  
Center at San Antonio

**Diana Simeonova, Dipl. Psych.,  
Ph.D.**

Emory University School of Medicine

**Nhi-Ha Trinh, M.D., MPH**

Depression Clinical and Research  
Program, Massachusetts General  
Hospital

**Gwyneth Zai, M.D., FRCPC, MSc**

Neurogenetics Section and  
Department of Psychiatry, Centre  
for Addiction and Mental Health,  
University of Toronto

**Clement Zai, Ph.D.**

Centre for Addiction and Mental Health

## AT-A-GLANCE

### Monday, June 16, 2014

7:30am – 8:30am **NIA Breakfast Roundtable (Invitation only)**  
Room 216

8:30am – 9:00am **Conference Opening**  
Grand Ballroom

9:00am – 10:30am **Panel Sessions**

*Recognizing and Treating Catatonia across the Diagnostic Spectrum: The Impact of New DSM-5 Classification	Risks Posed by Duplicate or Inappropriate Subjects in Clinical Trials and Methods for Mitigating the Risk	Research Forum: Meditative Practices, Underlying Neurobiological Mechanisms, and Application to Mental Health	*Biological Approaches To Treat Substances Use Disorders
Location: Diplomat 1-2	Location: Atlantic 1	Location: Atlantic 2	Location: Atlantic 3

10:30am – 10:45am **Break**  
Ballroom Foyers

10:45am – 12:15pm **Panel Sessions**

NIAAA Sponsored ACTIVE Update: Missing Data in Alcohol Use Disorder Clinical Trials - Issues and Analytic Methods	*Novel Treatments in Bipolar Disorder: Primary and Secondary Targets	Dimensional Symptom and Disability Measures in DSM-5	*Weighing In on Relative Risks of Fetal Exposure to Psychotropics and Psychiatric Disorders
Location: Diplomat 1-2	Location: Atlantic 1	Location: Atlantic 2	Location: Atlantic 3

*\*of special interest to clinicians*

12:15pm – 2:00pm

**Lunch On Own**

1:00pm – 2:00pm

**First Time Attendee Meet & Greet**

Atlantic 1

2:00pm – 4:00pm

**Pharmaceutical Pipeline Presentations**

Grand Ballroom

4:00pm – 4:15pm

**Break**

Ballroom Foyers

4:15pm – 5:45pm

**Panel Sessions**

Placebo Response, Response Variance and Antidepressant-placebo Differences in Recent Antidepressant Clinical Trials based on Three Patient Interview Models	*Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic Trial of Lithium vs. a Second Generation Antipsychotic for Bipolar Disorder	*NIAAA Panel Session: Advances in Treatments for PTSD and Alcohol Comorbidity	Novel and Underutilized Strategies to Improve Adherence and Reduce Relapse Risk in Schizophrenia
Location: Diplomat 1-2	Location: Atlantic 1	Location: Atlantic 2	Location: Atlantic 3

6:15pm – 7:45pm

**New Investigators' Award Ceremony & Reception (Invitation only)**

Diplomat 4-5

*\*of special interest to clinicians*

## FULL SCHEDULE

### Monday, June 16, 2014

**7:30am – 8:30am**      **NIA Breakfast Roundtable (Invitation only)**  
*Room 216*

**8:30am – 9:00am**      **Conference Opening**  
*Grand Ballroom*

### Panel Sessions

**9:00am – 10:30am**      **\*Recognizing and Treating Catatonia across the Diagnostic Spectrum: The Impact of New DSM-5 Classification**  
*Diplomat 1-2*

**Chair & Discussant:** Georgios Petrides, The Zucker Hillside Hospital

**9:00am – 9:10am**      **Introduction**

**9:10am – 9:30am**      **Catatonia: Video Workshop on Recognition and Management**  
Andrew Francis, SUNY Stony Brook

**9:30am – 9:50am**      **Pediatric Catatonia: Review and New Vagal Theory**  
Dirk M. Dhossche, University of Mississippi Medical Center

**9:50am – 10:10am**      **Longitudinal Assessment of the Psychomotor Dimension in Psychosis: Implications for Treatment**  
Stanley N. Caroff, Philadelphia VA Medical Center/  
University of Pennsylvania

**10:10am – 10:30am**      **Discussion**

*\*of special interest to clinicians*

**9:00am – 10:30am****Risks Posed by Duplicate or Inappropriate Subjects in Clinical Trials and Methods for Mitigating the Risk**  
*Atlantic 1***Chair:** Jonathan Rabinowitz, Bar Ilan University**Discussant:** Janet Williams, MedAvante, Inc.**9:00am – 9:10am****Introduction****9:10am – 9:30am****Evidence and Risks of Duplicate Subjects in Clinical Trials and How You Can Minimize the Risk**  
Jonathan Rabinowitz, Bar Ilan University**9:30am – 9:50am****The Professional Patient ‘Spectrum’ or Simply Inappropriate Patients: 50 Shades of Grey in Protocol Non-adherence**  
Michael Detke, Indiana University**9:50am – 10:10am****Proven Strategies to Mitigate the Risk of Enrolling Professional Subjects in Large Depression Studies**  
Brooke Geibel, Shire**10:10am – 10:30am****Discussion****9:00am – 10:30am****Research Forum: Meditative Practices, Underlying Neurobiological Mechanisms, and Application to Mental Health**  
*Atlantic 2***Chair:** Emmeline Edwards, NIH/NCCAM**Co-chair:** Kristen Huntley, NIH/NCCAM**Discussant:** David Shurtleff, NIH/NCCAM**9:00am – 9:10am****Introduction****9:10am – 9:30am****Neuroimaging as a Tool for the Study of Meditation**  
Kelvin O. Lim, University of Minnesota**9:30am – 9:50am****What is Known about the Effectiveness of Meditative Approaches for Resilience and Cognitive Enhancement?**  
Amishi Jha, University of Miami



<b>9:00am – 10:30am (continued)</b>	<b>Research Forum: Meditative Practices, Underlying Neurobiological Mechanisms, and Application to Mental Health</b> <i>Atlantic 2</i>
---	---

9:50am – 10:10am	<b>Innovation and Opportunities in Neuroscientific Research on Meditation</b> Richard J. Davidson, University of Wisconsin
------------------	---

10:10am – 10:30am	<b>Discussion</b>
-------------------	-------------------

<b>9:00am – 10:30am</b>	<b>*Biological Approaches to Treat Substances Use Disorders</b> <i>Atlantic 3</i>
-------------------------	--

**Chair:** Phil Skolnick, NIDA/NIH  
**Discussant:** Raye Litten, NIAAA

9:00am – 9:10am	<b>Introduction</b>
-----------------	---------------------

9:10am – 9:25am	<b>Genetically Engineered Butyrylcholinesterase (TV-1380): An Innovative Approach to Treat Cocaine Dependence</b> Phil Skolnick, NIDA/NIH
-----------------	--

9:25am – 9:40am	<b>Use of Functional Assays to Develop a Novel Anti-nicotine Vaccine</b> Heather L. Davis, Pfizer Vaccine Immunotherapeutics
-----------------	---

9:40am – 9:55am	<b>Development of a Heroin Vaccine</b> Gary R. Matyas, Walter Reed Army Institute of Research
-----------------	--

9:55am – 10:10am	<b>Continuing Towards Gene Transfer of Modified Human Butyrylcholinesterase to Treat Cocaine Addiction</b> Stephen Brimijoin, Mayo Clinic
------------------	--

10:10am – 10:30am	<b>Discussion</b>
-------------------	-------------------

<b>10:30am – 10:45am</b>	<b>Break</b> <i>Ballroom Foyers</i>
--------------------------	--

*\*of special interest to clinicians*

**Panel Sessions**

**10:45am – 12:15pm**      **NIAAA Sponsored ACTIVE Update: Missing Data in Alcohol Use Disorder Clinical Trials - Issues and Analytic Methods**  
*Diplomat 1-2*

**Chair:** Raymond F. Anton, Medical University of South Carolina

**Discussant:** Raye Z. Litten, NIAAA

**10:45am – 10:55am**      **Introduction**

**10:55am – 11:10am**      **Overview of the ACTIVE Workgroup and Mission and Importance of Missing Drinking Data in Alcohol Use Disorder Trials**

Raymond F. Anton, Medical University of South Carolina

**11:10am – 11:25am**      **How Does Drinking Change When People Stop Taking Medicines During a Clinical Trial? Implications for Missing Drinking Data Reduction and Imputation**

Robert L. Stout, Pacific Institute for Research and Evaluation

**11:25am – 11:40am**      **The Use of Pattern Mixture Models for Imputation and Analysis of Missing Drinking Data in Nalmfene Trials for Alcohol Dependence During Regulatory Approval in Europe**

Per Sorensen, H. Lundbeck A/S

**11:40am – 11:55am**      **Validity of Various Missing Drinking Data Imputation Methods – Results from Re-analysis of the US COMBINE Study**

Katie Witkiewitz, University of New Mexico

**11:55am – 12:15pm**      **Discussion**

**10:45am – 12:15pm**     **\*Novel Treatments in Bipolar Disorder: Primary and Secondary Targets**  
*Atlantic 1*

**Chair:** Katherine Burdick, Mount Sinai School of Medicine

**Discussant:** Terence Ketter, Stanford University School of Medicine

10:45am – 10:55am     **Introduction**

10:55am – 11:10am     **Methodological Considerations in the Design and Conduct of Acute Adjunctive Bipolar Depression Treatment Trials**  
Joseph R. Calabrese, Case Western Reserve School of Medicine

11:10am – 11:25am     **Effect of Lurasidone on Cognitive Impairment: From the Lab to the Clinic**  
Andrei Pikalov, Sunovion Pharmaceuticals, Inc.

11:25am – 11:40am     **Methodological Challenges to Cognitive Trials in Bipolar Disorder**  
Katherine Burdick, Mount Sinai School of Medicine

11:40am – 11:55am     **Interaction Effects between Affective Symptoms and Cognitive Function in Bipolar Disorder Clinical Trials**  
Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai

11:55am – 12:15pm     **Discussion**

**10:45am – 12:15pm**     **Dimensional Symptom and Disability Measures in DSM-5**  
*Atlantic 2*

**Chair:** William Narrow, American Psychiatric Association

**Discussant:** Lori Davis, Tuscaloosa VA Medical Center and University of Alabama School of Medicine

10:45am – 10:55am     **Introduction**

10:55am – 11:15am     **DSM-5 Cross-cutting Dimensional Measures: Reliability, Sensitivity to Change, and Association with Disability**  
Diana E. Clarke, American Psychiatric Association

*\*of special interest to clinicians*

**10:45am – 12:15pm**  
**(continued)**      **Dimensional Symptom and Disability Measures in DSM-5**  
*Atlantic 2*

11:15am – 11:35am      **DSM-5 Dimensional Symptom and Disability Measures in Routine Clinical Practice Settings**  
Eve K. Mościcki, American Psychiatric Association

11:35am – 11:55am      **The World Health Organization Disability Assessment Schedule in the DSM-5 Field Trials: Associations with Psychiatric Diagnosis**  
William Narrow, American Psychiatric Association

11:55am – 12:15pm      **Discussion**

**10:45am – 12:15pm**      **\*Weighing In on Relative Risks of Fetal Exposure to Psychotropics and Psychiatric Disorders**  
*Atlantic 3*

**Chair:** Lee S. Cohen, Massachusetts General Hospital

**Co-chair & Discussant:** Marlene Freeman, Massachusetts General Hospital

10:45am – 10:55am      **Introduction**

10:55am – 11:15am      **The National Pregnancy Registry for Atypical Antipsychotics: Effects of Fetal Exposure on Risk for Congenital Malformations and Maternal and Newborn Outcomes**  
Lee S. Cohen, Massachusetts General Hospital

11:15am – 11:35am      **Prenatal Exposure to SSRIs: Sorting the Ever-growing Data**  
Sonia Hernandez-Diaz, Harvard School of Public Health

11:35am – 11:55am      **Impact of Maternal Psychiatric Illness on Fetal, Obstetrical and Neonatal Wellbeing**  
Margaret Altemus, Weill Medical College, Cornell University

11:55am – 12:15pm      **Discussion**

**12:15pm – 2:00pm**      **Lunch On Own**

**1:00pm – 2:00pm**      **First Time Attendee Meet & Greet**  
*Atlantic 1*

*\*of special interest to clinicians*

**2:00pm – 4:00pm      Pharmaceutical Pipeline Presentations**  
**Grand Ballroom**

**Chair:** Carlos Zarate, National Institute of Mental Health

**2:00pm – 2:10pm      A Pilot Study of a Novel Monoamine Triple Reuptake Inhibitor EB-1020 SR in the Treatment of ADHD in Adults**

Timothy Wilens, Massachusetts General Hospital

**2:10pm – 2:20pm      Metadoxine Extended Release (MDX): A Novel Drug Candidate for the Treatment of ADHD & Other Cognitive Disorders**

Jonathan Rubin, Alcobra Pharma

**2:20pm – 2:30pm      A Rapidly Acting Intranasal Treatment for the Symptoms of GAD**

Michael R. Liebowitz, Pherin Pharmaceuticals

**2:30pm – 2:40pm      Lupron in Combination with an Acetylcholinesterase Inhibitor Halts Cognitive Decline in Women with Alzheimer's Disease over a 48 Week Period**

Richard Bowen, OTB Research

**2:40pm – 2:50pm      Efficacy and Safety of a Novel mGlu2 Receptor Positive Allosteric Modulator as an Adjunctive Treatment to an SSRI/SNRI in the Treatment of Anxious Depression**

Justine Kent, Janssen

**2:50pm – 3:00pm      A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Intravenous Ketamine in Patients with Treatment-resistant Depression**

Jaskaran Singh, Janssen Research and Development, LLC

**3:00pm – 3:10pm      Randomized, Double-blind, Active-controlled, Phase 2/3 Study to Determine the Short-term (6-Week) and Long-term (6 Month) Cognitive and Anti-psychotic Efficacy, Safety and Tolerability of CYP-1020 Compared to Risperidone**

Jonathan Rabinowitz, Bar Ilan University

**2:00pm – 4:00pm  
(continued)**

**Pharmaceutical Pipeline Presentations**  
*Grand Ballroom*

3:10pm – 3:20pm

**Results of a Phase 2B Clinical Trial of TC-5619, a Selective Alpha 7 Neuronal Nicotinic Receptor (NNR) Agonist in the Adjunctive Treatment of Negative Symptoms and Cognitive Dysfunction in Schizophrenia**

David Hosford, Targacept, Inc.

3:20pm – 3:30pm

**AZD8529, a Positive Allosteric Modulator of the mGluR2 Receptor for the Treatment of Schizophrenia**

Alan Cross, AstraZeneca Neuroscience Innovative Medicines Unit

3:30pm – 3:40pm

**Advancing ITI-007: A Novel Product Candidate for the Treatment of Schizophrenia, Bipolar Disorder and Other Neuropsychiatric Indications**

Kimberly E. Vanover, Intra-Cellular Therapies, Inc.

**4:00pm – 4:15pm**

**Break**  
*Ballroom Foyers*

**Panel Sessions**

**4:15pm – 5:45pm**

**Placebo Response, Response Variance and Antidepressant-placebo Differences in Recent Antidepressant Clinical Trials Based on Three Patient Interview Models**

*Diplomat 1-2*

**Chair:** Arif Khan, Northwest Clinical Research Center

**Discussant:** Walter Brown, Brown University

4:15pm – 4:25pm

**Introduction**

4:25pm – 4:45pm

**Examining the Utility and Futility of Surveillance Strategies for CNS Trials**

Steven D. Targum, Clintara, LLC

4:15pm – 5:45pm (continued)	<b>Placebo Response, Response Variance and Antidepressant-placebo Differences in Recent Antidepressant Clinical Trials Based on Three Patient Interview Models</b> <i>Diplomat 1-2</i>
4:45pm – 5:05pm	<b>The Use of Blinded, Independent, Remote Ratings in Psychiatric Clinical Trials: The Good, the Bad, and the Appropriate Situation</b> Michael Detke, Indiana University
5:05pm – 5:25pm	<b>Magnitude of Placebo Response and Response Variance in Antidepressant Clinical Trials using Enhanced Interviews Techniques Compared to Traditional Rating Interviews</b> Arif Khan, Northwest Clinical Research Center
5:25pm – 5:45pm	<b>Discussion</b>
4:15pm – 5:45pm	<b>*Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic Trial of Lithium vs. a Second Generation Antipsychotic for Bipolar Disorder</b> <i>Atlantic 1</i>
<b>Chair:</b> Terence Ketter, Stanford University School of Medicine <b>Co-chair:</b> Andrew Nierenberg, Massachusetts General Hospital <b>Discussant:</b> Mauricio Tohen, University of New Mexico	
4:15pm – 4:25pm	<b>Introduction</b>
4:25pm – 4:45pm	<b>Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): Rationale, Design, and Demographics</b> Edward S. Friedman, University of Pittsburgh School of Medicine
4:45pm – 5:05pm	<b>Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness)</b> Andrew Nierenberg, Massachusetts General Hospital

*\*of special interest to clinicians*

4:15pm – 5:45pm  
(continued)

**\*Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic Trial of Lithium vs. a Second Generation Antipsychotic for Bipolar Disorder**  
*Atlantic 1*

5:05pm – 5:25pm

**Bipolar CHOICE Safety and Tolerability Outcomes: Focus on Obesity and Cardiometabolic Health**  
David Kemp, Case Western Reserve University

5:25pm – 5:45pm

**Discussion**

4:15pm – 5:45pm

**\*NIAAA Panel Session: Advances in Treatments for PTSD and Alcohol Comorbidity**  
*Atlantic 2*

**Chair:** Raye Z. Litten, NIAAA

**Co-chair:** Ismene L. Petrakis, Yale University School of Medicine

**Discussant:** Raye Z. Litten, NIAAA

4:15pm – 4:25pm

**Introduction**

4:25pm – 4:45pm

**Pharmacotherapy of Patients with Post Traumatic Stress Disorder (PTSD) and Comorbid Alcohol Use Disorders among Veterans**  
Ismene L. Petrakis, Yale University School of Medicine

4:45pm – 5:05pm

**Prazosin for Comorbid PTSD and Alcohol Dependence: A Pilot Randomized Clinical Trial**  
Tracy Simpson, VA Puget Sound Health Care System

5:05pm – 5:25pm

**Effective Treatment Strategies for Patients with Concurrent PTSD and Addiction**  
David Oslin, University of Pennsylvania

5:25pm – 5:45pm

**Discussion**

*\*of special interest to clinicians*



<b>4:15pm – 5:45pm</b>	<b>Novel and Underutilized Strategies to Improve Adherence and Reduce Relapse Risk in Schizophrenia</b> <i>Atlantic 3</i>
<b>Chair:</b> Christoph Correll, The Zucker Hillside Hospital <b>Discussant:</b> Nina R. Schooler, SUNY Downstate Medical Center	
<b>4:15pm – 4:25pm</b>	<b>Introduction</b>
<b>4:25pm – 4:40pm</b>	<b>Response, Remission and Recovery in Schizophrenia</b> John M. Kane, The Zucker Hillside Hospital
<b>4:40pm – 4:55pm</b>	<b>Effect of Trial Design, Population and Illness Phase on the Role of Long-acting Injectable Antipsychotics for Signaling and Preventing Non-adherence in Schizophrenia</b> Christoph Correll, The Zucker Hillside Hospital
<b>4:55pm – 5:10pm</b>	<b>Leveraging Novel Technologies to Enhance Adherence</b> Adam Hanina, Ai Cure Technologies
<b>5:10pm – 5:25pm</b>	<b>Technology-based Approaches for the Detection and Prevention of Relapse in Schizophrenia</b> Dror Ben-Zeev, Dartmouth College
<b>5:25pm – 5:45pm</b>	<b>Discussion</b>
<b>6:15pm – 7:45pm</b>	<b>New Investigators' Award Ceremony &amp; Reception (Invitation only)</b> <i>Diplomat 4-5</i>

[illegible]

## AT-A-GLANCE

### Tuesday, June 17, 2014

6:45am – 8:00am	<b>15th Annual Fun Run/Walk</b> Meet in Main Lobby
7:00am – 8:30am	<b>ASCP Board Meeting (Invitation only)</b> Room 217
7:30am – 8:30am	<b>NIA Breakfast Roundtable (Invitation only)</b> Room 216
7:30am – 9:00am	<b>Morning Break</b> Ballroom Foyers
8:30am – 10:00am	<b>Regulatory Plenary: FDA Science Initiatives: A Brief Update</b> Grand Ballroom
10:00am – 10:15am	<b>Break</b> Ballroom Foyers
10:15am – 11:15am	<b>ASCP Lifetime Awardee Presentation – A. John Rush: Bridging the Chasm between Research and Practice</b> Grand Ballroom
11:15am – 1:00pm	<b>Poster Session I with Lunch</b> Regency Ballroom
1:15pm – 2:45pm	<b>Panel Sessions</b>

*Overcoming the Shortcomings of Treatment Practice Guidelines for Mood and Psychotic Disorders	NIMH/NCCAM Panel: Conducting Pragmatic Trials in Mental Health: Lessons Learned from the NIH Health Care Systems Research Collaboratory	Inflammation and Insulin Resistance: Implications for Pathophysiology and Treatment	*Long Acting Injectable Antipsychotics: Perspectives on their Role in Schizophrenia Treatment
Location: Diplomat 1-2	Location: Atlantic 1	Location: Atlantic 2	Location: Atlantic 3

*\*of special interest to clinicians*

2:45pm – 3:15pm

**ASCP Business Meeting (ASCP Members Only)**  
Grand Ballroom

3:15pm – 3:30pm

**Break**  
Ballroom Foyers

3:30pm – 4:30pm

**Individual Research Reports**

Anxiety Disorder Presentations	Depression Presentations	Schizophrenia and Bipolar Disorder Presentations	Statistical Methods, Personality Disorders, Substance Abuse, and Comorbidity Presentations
Location: Diplomat 1-2	Location: Atlantic 1	Location: Atlantic 2	Location: Atlantic 3

4:30pm – 4:45pm

**Break**  
Ballroom Foyers

4:45pm – 6:45pm

**Workshops**

Cognitive Deficits in Depression: What are They? Are They Independent Dimensions? Are They Targets for Treatment?	*Psychopharmacology of Residual Symptoms in Mood Disorders and Schizophrenia	New Approaches to Funding Clinical Trials at NIMH
Location: Atlantic 1	Location: Atlantic 2	Location: Atlantic 3

7:00pm – 8:00pm

**ASCP Reception**  
South Palm Court

9:00pm – 12:00am

**Black & White Affair, hosted by Zane Courbay**  
Room 3641

*\*of special interest to clinicians*

## FULL SCHEDULE

### Tuesday, June 17, 2014

6:45am – 8:00am	<b>15th Annual Fun Run/Walk</b> <i>Meet in Main Lobby</i>
7:00am – 8:30am	<b>ASCP Board Meeting (Invitation only)</b> <i>Room 217</i>
7:30am – 8:30am	<b>NIA Breakfast Roundtable (Invitation only)</b> <i>Room 216</i>
7:30am – 9:00am	<b>Morning Break</b> <i>Ballroom Foyers</i>
8:30am – 10:00am	<b>Regulatory Plenary: FDA Science Initiatives: A Brief Update</b> <i>Grand Ballroom</i>

**Chair:** Ni A. Khin, M.D., U.S. Food and Drug Administration

This session will provide updates on regulatory initiatives from the US Food and Drug Administration (FDA). Dr. Ni Khin will give a brief overview of the joint FDA initiative with European Medicines Agency (EMA) to ensure data quality in clinical trials and good clinical practice compliance. Dr. Celia Winchell from FDA's Division of Anesthesia and Analgesia Products (DAAP) will discuss the challenges of determining efficacy endpoints in clinical trials for addiction treatment drugs. Specifically, she will discuss how DAAP identified a pattern of alcohol use as an alternative endpoint to complete abstinence based on recent analyses of data. Dr. Silvana Borges from FDA's Division of Psychiatry Products will present preliminary findings regarding use of active controls in depression trials. There will be an informal discussion with the audience on these selected topics as well as other regulatory issues of common interest within this context.

8:30am – 8:45am	Ni A. Khin, M.D., Food and Drug Administration
8:45am – 9:05am	Celia Winchell, M.D., Food and Drug Administration
9:05am – 9:25am	Silvana Borges, M.D., Food and Drug Administration
9:25am – 10:00am	Panel Discussion and Q&A

**10:00am – 10:15am**

**Break**  
**Ballroom Foyers**

**10:15am – 11:15am**

**ASCP Lifetime Awardee Presentation – A. John Rush: Bridging the Chasm between Research and Practice**  
**Grand Ballroom**

Patient centered research and comparative effectiveness research address practical issues that aim at addressing patients' concerns or choices among treatments, respectively. In addition to these important objectives, clinicians need to better understand how to deliver each treatment; to whom to deliver (or not) particular treatments; when to discontinue, switch, or augment a specific treatment; and for whom which specific treatment sequences are indicated. This presentation discusses practical, simple, efficient research design, measurement and analytic options, that could address these important clinical knowledge gaps with the aim of improving patient outcomes and treatment cost efficiencies.

**11:15am – 1:00pm**

**Poster Session I with Lunch**  
**Regency Ballroom**  
**\*See Pages 69 through 80 for poster listing.**

## Panel Sessions

**1:15pm – 2:45pm**

**\*Overcoming the Shortcomings of Treatment Practice Guidelines for Mood and Psychotic Disorders**  
**Diplomat 1-2**

**Chair:** Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai  
**Discussant:** Michael E. Thase, Perelman School of Medicine of the University of Pennsylvania

**1:15pm – 1:25pm**

**Introduction**

**1:25pm – 1:45pm**

**Practice Guidelines for Bipolar Disorder: What's Useful, What's Not, and What's Missing**  
Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai

**\*of special interest to clinicians**

**1:15pm – 2:45pm  
(continued)**

**\*Overcoming the Shortcomings of Treatment  
Practice Guidelines for Mood and Psychotic  
Disorders  
*Diplomat 1-2***

1:45pm – 2:05pm

**Treatment Guidelines for MDD: Evidence-based,  
Eminence-based, or Faith-based?**  
Alan J. Gelenberg, Penn State College of Medicine

2:05pm – 2:25pm

**Practice Guidelines for Treatment of  
Schizophrenia: Consensus or Confusion?**  
Peter J. Weiden, UIC Medical Center

2:25pm – 2:45pm

**Discussion**

**1:15pm – 2:45pm**

**NIMH/NCCAM Panel: Conducting Pragmatic Trials  
in Mental Health: Lessons Learned from the NIH  
Health Care Systems Research Collaboratory  
*Atlantic 1***

**Chair & Discussant:** Emmeline Edwards, NIH, NCCAM

**Co-chair:** Wendy Weber, NIH, NCCAM

1:15pm – 1:25pm

**Introduction**

1:25pm – 1:45pm

**Conducting Pragmatic Trials in Mental Health:  
Lessons Learned from the NIH Health Care  
Systems Research Collaboratory**  
Wendy Weber, NIH, NCCAM

1:45pm – 2:05pm

**Pragmatic Trial of Population-based Program to  
Prevent Suicide Attempts**  
Greg Simon, Group Health Research Institute

2:05pm – 2:25pm

**NIMH/NCCAM Panel: Conducting Pragmatic Trials  
in Mental Health: Lessons Learned from the NIH  
Health Care Systems Research Collaboratory**  
Liz Delong, Duke University Medical Center

2:25pm – 2:45pm

**Discussion**

*\*of special interest to clinicians*

**1:15pm – 2:45pm**

**Inflammation and Insulin Resistance: Implications for Pathophysiology and Treatment**  
*Atlantic 2*

**Chair:** David Kemp, Case Western Reserve University

**Discussant:** Madhukar Trivedi, UT Southwestern

1:15pm – 1:20pm

**Introduction**

1:20pm – 1:35pm

**PPAR- $\gamma$  Agonism as a Modulator of Mood: Proof-of-concept for Pioglitazone in Bipolar Depression**  
David Kemp, Case Western Reserve University

1:35pm – 1:50pm

**Association between Kynurenine-pathway Metabolites and Gray Matter Volumes of the Hippocampus and Amygdala in Patients with Mood Disorders**  
Jonathan Savitz, Laureate Institute for Brain Research

1:50pm – 2:05pm

**Trait and State Patterns of Inflammatory Biomarkers in Bipolar Disorder**  
Jess G. Fiedorowicz, University of Iowa

2:05pm – 2:20pm

**Biomarkers of Illness Activity in Bipolar Disorder**  
Flavio Kapczinski, Federal University of Rio Grande do Sul

2:20pm – 2:45pm

**Discussion**

**1:15pm – 2:45pm**

**\*Long Acting Injectable Antipsychotics: Perspectives on their Role in Schizophrenia Treatment**  
*Atlantic 3*

**Chair:** Nina R. Schooler, SUNY Downstate Medical Center

**Discussant:** John M. Kane, The Zucker Hillside Hospital

1:15pm – 1:25pm

**Introduction**

1:25pm – 1:45pm

**Long Acting Injectable vs. Oral Antipsychotics for Schizophrenia: Meta-analytic Consideration of the True Effect Size by the Study Designs**  
Taishiro Kishimoto, Keio University School of Medicine, Department of Psychiatry

*\*of special interest to clinicians*



**1:15pm – 2:45pm  
(continued)**

**\*Long Acting Injectable Antipsychotics:  
Perspectives on their Role in Schizophrenia  
Treatment  
*Atlantic 3***

**1:45pm – 2:05pm**

**PROACTIVE: Exploring Longitudinal Course to  
Understand Treatment Outcomes in LAI - oral  
Comparisons**  
Nina R. Schooler, SUNY Downstate Medical Center

**2:05pm – 2:25pm**

**A Comparison of Long-acting Antipsychotic  
Medications for Schizophrenia (ACLAIMS)**  
Joseph P. McEvoy, Georgia Regents University

**2:25pm – 2:45pm**

**Discussion**

**2:45pm – 3:15pm**

**ASCP Business Meeting (ASCP Members Only)  
*Grand Ballroom***

**3:15pm – 3:30pm**

**Break  
*Ballroom Foyers***

## Individual Research Reports

**3:30pm – 4:30pm**

**Anxiety Disorder Presentations  
*Diplomat 1-2***

**Chair:** Crystal Clark, Northwestern University Feinberg School of Medicine  
Asher Center for the Study and Treatment of Depressive Disorders

**3:30pm – 3:45pm**

**A Rapidly Acting Intranasal Treatment for the  
Symptoms of GAD**  
Michael R. Liebowitz, Pherin Pharmaceuticals

**3:45pm – 4:00pm**

**Comparative Effectiveness of Prolonged Exposure  
(PE) and Sertraline(SER) in PTSD: Final Analyses  
of The Impact of Choice and Treatment Preference  
on Acute Outcome**  
Matig Mavissakalian, Case Western Reserve  
University School of Medicine

*\*of special interest to clinicians*

**3:30pm – 4:30pm  
(continued)**

**Anxiety Disorder Presentations  
*Diplomat 1-2***



4:00pm – 4:15pm

**Pharmacogenetic Study of Genetic Variations across Remote Regulatory Regions of 14 Obsessive-Compulsive Disorder Candidate Genes in Antidepressant Response**  
Gwyneth Zai, University of Toronto

4:15pm – 4:30pm

**Emotion Recognition Deficits in Treated and Untreated Adults with ADHD**  
Anneka Tomlinson, University of Manchester

**3:30pm – 4:30pm**

**Depression Presentations  
*Atlantic 1***

**Chair:** Bradley Gaynes, University of North Carolina School of Medicine

3:30pm – 3:45pm

**The Efficacy of Vortioxetine in Patients with Major Depressive Disorder and High Levels of Anxiety Symptoms: A Meta-analysis**  
David Baldwin, University of Southampton



3:45pm – 4:00pm

**Erythropoietin Induces Growth in Left Hippocampus and Improves Verbal Memory in Patients with Severe Affective Disorders**  
Kamilla Woznica Miskowiak, Copenhagen University Hospital



4:00pm – 4:15pm

**Epidural Cortical Stimulation of the Left DLPFC Leads to Dose-dependent Enhancement of Working Memory in Patients with MDD**  
Joan A. Camprodon, Massachusetts General Hospital, Harvard Medical School

4:15pm – 4:30pm

**A Phase 1B, Randomized, Double-blind, Placebo-controlled, Multiple-dose Escalation Study Evaluating the Effects of NSI-189 Phosphate, a Neurogenic Compound, in Patients with Major Depressive Disorder (MDD)**  
Marlene Freeman, Massachusetts General Hospital



= New Investigator

## 3:30pm – 4:30pm **Schizophrenia and Bipolar Disorder Presentations** *Atlantic 2*

**Chair:** Kristina Deligiannidis, University of Massachusetts Medical School/  
UMass Memorial Medical Center

3:30pm – 3:45pm **Can Oxytocin Enhance Learning during Social Cognitive Skills Training in Schizophrenia?**  
Michael C. Davis, VA Greater Los Angeles, University of California Los Angeles

3:45pm – 4:00pm **Hospitalization Rates in Patients Switched from Oral Antipsychotics to Aripiprazole Once-monthly: A Mirror Study**  
Timothy Peters-Strickland, Otsuka Pharmaceutical Development & Commercialization, Inc.

4:00pm – 4:15pm **Lithium Enhances Mitochondrial Complex I Activity and Ameliorates DNA Methylation and Hydroxymethylation Induced by Mitochondrial Complex I Dysfunction**  
Ana Cristina Andreazza, University of Toronto

4:15pm – 4:30pm **Varenicline for Smoking Cessation in Bipolar Disorder: A Double-blind, Randomized, Placebo-controlled Trial**  
Roy K.N. Chengappa, University of Pittsburgh

## 3:30pm – 4:30pm **Statistical Methods, Personality Disorders, Substance Abuse, and Comorbidity Presentations** *Atlantic 3*

**Chair:** Katherine Burdick, Mount Sinai School of Medicine



3:30pm – 3:45pm **Brain-derived Neurotrophic Factor Genotype and Amygdala Habituation in Borderline Personality Disorder**  
M. Mercedes Perez-Rodriguez, Mount Sinai School of Medicine

3:45pm – 4:00pm **Analysis and Missing Data Handling in Psychiatry Trials with Inevitable, High, Differential and Informative Discontinuations**  
Yangchun Du, Alkermes, Inc.



= New Investigator

**3:30pm – 4:30pm  
(continued)**

**Statistical Methods, Personality Disorders,  
Substance Abuse, and Comorbidity Presentations**  
*Atlantic 3*

**4:00pm – 4:15pm**

**Long-term Skeletal Effects of Risperidone and  
SSRIs in Youths**

Chadi Calarge, University of Iowa

**4:15pm – 4:30pm**

**Impulsivity and Substance Dependence: Meta-  
analysis and Possible Role in Treatment**

Saddichha Sahoo, NIMHANS

**4:30pm – 4:45pm**

**Break**  
*Ballroom Foyers*

## Workshops

**4:45pm – 6:45pm**

**Cognitive Deficits in Depression: What are they?  
Are they Independent Dimensions? Are they  
Targets for Treatment?**  
*Atlantic 1*

**Chair:** Steven D. Targum, Clintara, LLC

**Co-chair:** Craig Nelson, UCSF

**Discussant:** Tiffany Farchione, US Food and Drug Administration

**4:45pm – 4:50pm**

**Introduction**

**4:50pm – 5:10pm**

**Cognitive Impairment in Late Life Depression:  
Type, Frequency, and Methods of Assessment**

Scott Mackin, University of California, San Francisco

**5:10pm – 5:30pm**

**Effects of Treatment on Cognition in Late Life  
Depression**

Craig Nelson, UCSF

**5:30pm – 5:50pm**

**Changes in Cognitive Symptoms before and  
after Buspirone-melatonin Treatment for Major  
Depressive Disorder**

Steven D. Targum, Clintara, LLC

**5:50pm – 6:10pm**

**Changes in Cognitive Symptoms before and  
after Vortioxetine Treatment in Major Depressive  
Disorder**

Maurizio Fava, Massachusetts General Hospital

<b>4:45pm – 6:45pm (continued)</b>	<b>Cognitive Deficits in Depression: What are they? Are they Independent Dimensions? Are they Targets for Treatment?</b> <i>Atlantic 1</i>
6:10pm – 6:30pm	<b>Deficits in Mood Disorders: Impact on Functional Outcomes and Treatment Strategies</b> Dan V. Iosifescu, Icahn School of Medicine at Mount Sinai
6:30pm – 6:45pm	<b>Discussion</b>
<b>4:45pm – 6:45pm</b>	<b>*Psychopharmacology of Residual Symptoms in Mood Disorders and Schizophrenia</b> <i>Atlantic 2</i>
<b>Chair:</b> Jonathan Alpert, Massachusetts General Hospital, Harvard Medical School	
<b>Discussant:</b> Richard Shelton, University of Alabama at Birmingham	
4:45pm – 4:50pm	<b>Introduction</b>
4:50pm – 5:15pm	<b>Methodological and Design Issues in Augmentation Trials</b> Thomas Laughren, MGH CTNI
5:15pm – 5:40pm	<b>New Approaches to the Treatment of Residual Symptoms of Schizophrenia</b> Donald C. Goff, NYU Medical School
5:40pm – 6:05pm	<b>Residual Symptoms in Bipolar Disorder: The Role of Polypharmacy</b> Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai
6:05pm – 6:30pm	<b>Studying the Efficacy of Adjunctive Therapies for Depressive Disorders</b> Michael E. Thase, Perelman School of Medicine of the University of Pennsylvania
6:30pm – 6:45pm	<b>Discussion</b>

*\*of special interest to clinicians*

**4:45pm – 6:45pm**

**New Approaches to Funding Clinical Trials at NIMH  
*Atlantic 3***

**Chair:** William Potter, National Institute of Mental Health

**Discussant:** David Kupfer, University of Pittsburgh School of Medicine

4:45pm – 5:00pm

**Introduction**

5:00pm – 5:20pm

**First in Human and Early Stage Clinical Trials  
of Novel Investigational Drugs or Devices for  
Psychiatric Disorders**

Meg Grabb, National Institute of Mental Health

5:20pm – 5:40pm

**Exploratory Clinical Trials of Novel Interventions  
for Mental Disorders**

Jill Heemskerk, National Institute of Mental Health

5:40pm – 6:00pm

**Pilot Effectiveness Studies and Services Research  
Grants**

Chris Sarampote, National Institute of Mental Health

6:00pm – 6:45pm

**Discussion**

**7:00pm – 8:00pm**

**ASCP Reception  
*South Palm Court***

## AT-A-GLANCE

### Wednesday, June 18, 2014

7:00am – 8:30am	<b>ASCP Steering Committee Meeting (Invitation only)</b> Room 308
7:30am – 8:30am	<b>NIA Breakfast Roundtable (Invitation only)</b> Room 216
7:30am – 9:00am	<b>Morning Break</b> Ballroom Foyers
8:15am – 9:45am	<b>Keynote Session: New Approaches to Mental Illness in the Era of the National Brain Initiative</b> Grand Ballroom
9:45am – 10:00am	<b>Break</b> Ballroom Foyers
10:00am – 12:00pm	<b>Plenary Session – NIH Institute Directors</b> Grand Ballroom
12:00pm – 2:00pm	<b>Poster Session II with Lunch</b> Regency Ballroom
2:00pm – 3:30pm	<b>Updates Session – The Latest on Treatment of Mood, OCD-spectrum, and Binge Eating Disorders</b> Grand Ballroom
3:30pm – 3:45pm	<b>Break</b> Ballroom Foyers
3:45pm – 5:45pm	<b>Workshops</b>

New Approaches to Drug Studies for Treating Social Deficits in Autism Spectrum Disorder	*Novel Mechanisms of Action for the Treatment of Depression and Anxiety: Scientific Updates	*Psychiatry and Technology: A Partnership in Promoting Mental Health
Location: Atlantic 1	Location: Atlantic 2	Location: Atlantic 3

*\*of special interest to clinicians*

[illegible]



## FULL SCHEDULE

### Wednesday, June 18, 2014

7:00am – 8:30am	<b>ASCP Steering Committee Meeting (Invitation only)</b> <i>Room 308</i>
7:30am – 8:30am	<b>NIA Breakfast Roundtable (Invitation only)</b> <i>Room 216</i>
7:30am – 9:00am	<b>Morning Break</b> <i>Ballroom Foyers</i>
8:15am – 9:45am	<b>Keynote Session: New Approaches to Mental Illness in the Era of the National Brain Initiative</b> <i>Grand Ballroom</i>

**Chair:** Husseini K. Manji, M.D., FRCP, Johnson & Johnson

Brain disorders are among mankind's most devastating illnesses. Worldwide, they place an enormous societal burden on those affected. Indeed, in the United States alone this burden of illness is rapidly approaching \$1 trillion annually, a number that is only likely to escalate in coming years with the aging population. In this plenary session, Drs. Manji and Insel and Mr. Kennedy will discuss interrelated facets in our search to better understand the mechanisms underlying a wide range of mental illnesses and to develop effective new treatments for them.

Rapid advances in science and technology over the past decade have provided us with an unprecedented opportunity and the tools needed to unlock the secrets of the brain. Dr. Insel will discuss the many significant advances that have recently been made towards understanding serious mental illnesses. Although public and private resources devoted to research in this area are diminishing, a host of cutting-edge approaches—from genomics to data mining, proteomics to biomarkers, pathway modeling to protein engineering, neuroimaging to optogenetics—is nevertheless revolutionizing the way we think about, study, and approach the development of urgently needed novel treatments for mental disorders, with extremely promising results.

**8:15am – 9:45am  
(continued)**

**Keynote Session: New Approaches to Mental Illness in the Era of the National Brain Initiative  
*Grand Ballroom***

Dr. Manji will discuss the paradigm shift that must accompany future research in this area. This includes not only moving from a ‘diagnose and treat’ approach to a ‘predict and pre-empt’ model, but the need to develop novel solutions that encompass meaningful and measurable patient outcomes (for instance, the ability to rapidly resume social and work responsibilities).

Mr. Kennedy will discuss the many social issues that can and must be addressed in any “whole-world” view of mental illness, including parity for mental health, ending the discrimination against patients, and the travesty of homeless and imprisoned individuals suffering from mental disorders.

The session will emphasize the speakers’ commitment to a strong, united, cross-disciplinary approach towards a key common goal: to work together across industry, academia, government, and the private sector in a concerted effort to improve the lives of the millions of individuals affected by brain disorders. With such a cooperative effort, real, tangible progress can be made.

**8:15am – 8:25am**

Introduction  
Husseini K. Manji, M.D., FRCPC, Johnson & Johnson

**8:25am – 8:55am**

Thomas Insel, M.D., NIMH

**8:55am – 9:25am**

Patrick Kennedy, Former US Representative & Mental Health Activist

**9:25am – 9:45am**

Discussion

**9:45am – 10:00am**

**Break  
*Ballroom Foyers***

**10:00am – 12:00pm      Plenary Session – NIH Institute Directors  
Grand Ballroom**

**Chair:** David Kupfer, M.D., University of Pittsburgh School of Medicine

This year's Institute Director's session will bring together directors from various NIH institutes who all have a similar goal of searching for new approaches in the research of mental disorders. Each director will have ten minutes to discuss what activities are going on within their institute regarding this goal. Thomas Insel, NIMH Director, will begin the session discussing transformation of clinical trials. Phil Skolnick will discuss one of the more challenging issues that NIDA faces is the epidemic of (both prescription and non-prescription) opiate abuse. To put the problem in perspective, it has been estimated that there are 3 million Americans currently abusing opioids; more deaths result from opiate overdose than from firearms. He will overview NIDA's efforts to combat both opiate abuse and overdose deaths. Kenneth Warren of NIAAA will discuss the current framework for medications development of alcohol use disorders. Josephine Briggs will discuss NCCAM's interest in encouraging work on the neuroscience of the mind-body interface and the mechanisms by which meditative practices such as mindfulness, hypnosis, and meditative exercise forms may impact on pain processing. Christopher Austin will address NCATS' unique role in the biomedical ecosystem and the translational science problems being prioritized by NCATS. He will also give an overview of the Center's programs and collaborative opportunities. Finally, Richard Nakamura will discuss the Center for Scientific Review's steps to measure and improve the performance of peer review. The session will continue with an open dialogue Q&A session with audience interaction.

Thomas Insel, M.D., NIMH  
Phil Skolnick, Ph.D., NIDA  
Kenneth Warren, Ph.D., NIAAA  
Josephine Briggs, M.D., NCCAM  
Christopher Austin, M.D., NCATS  
Richard Nakamura, Ph.D., CSR

12:00pm – 2:00pm

**Poster Session II with Lunch**

***Regency Ballroom***

***\*See Pages 81 through 92 for poster listing.***

2:00pm – 3:30pm

**Updates Session – The Latest on Treatment of Mood, OCD-spectrum, and Binge Eating Disorders**  
***Grand Ballroom***

**Chair:** Maurizio Fava, Massachusetts General Hospital

Recent advances in clinical neuroscience have led to the development of novel treatments of mood, OCD-spectrum, and binge eating disorders. The purpose of this symposium is to provide an overview of the latest developments in the pharmacological treatments for these conditions. Dr. Papakostas will review new approaches to the treatment of depression, as well as to the identification of subpopulations of depressed patients more likely to benefit from a given treatment. Dr. Ketter will present an update on new therapeutic developments in the treatment of bipolar disorder, such as the approval by the FDA of asenapine, risperidone long-acting injectable (LAI), ziprasidone, aripiprazole, and lurasidone therapy for bipolar disorder. In addition, Dr. Ketter will discuss the International Society for Bipolar Disorders (ISBD) Antidepressant Use in Bipolar Disorders Task Force controversial report from 2013. Finally, Dr. Ketter will present data concerning some novel pharmacological treatments for bipolar disorder. Dr. McElroy will also provide an overview of the treatments for hoarding disorder and binge eating disorder, new discrete diagnostic entities in DSM-5. Psychological treatments are effective for both conditions, but not all patients respond and pharmacotherapy is emerging as an important treatment option. Serotonin reuptake inhibitors have been the most widely studied agents, but both conditions respond modestly at best to these compounds. Newer agents showing promise include antiepileptics and psychostimulants. Available research on the pharmacotherapy of HD and BED will be reviewed, and future directions will be discussed.

2:00pm – 2:20pm

**Hoarding Disorder and Binge Eating Disorder**

Susan McElroy, University of Cincinnati College of Medicine

<b>2:00pm – 3:30pm (continued)</b>	<b>Updates Session – The Latest on Treatment of Mood, OCD-spectrum, and Binge Eating Disorders</b> <i>Grand Ballroom</i>
--	---

2:20pm – 2:40pm	<b>Update on Bipolar Disorder Pharmacotherapy</b> Terence Ketter, Stanford University School of Medicine
-----------------	---

2:40pm – 3:00pm	<b>Update on Treatment of Major Depressive Disorder</b> George I. Papakostas, Massachusetts General Hospital, Harvard Medical School
-----------------	---

3:00pm – 3:30pm	<b>Discussion</b>
-----------------	-------------------

3:30pm – 3:45pm	<b>Break</b> Ballroom Foyers
-----------------	---------------------------------

## Workshops

<b>3:45pm – 5:45pm</b>	<b>New Approaches to Drug Studies for Treating Social Deficits in Autism Spectrum Disorder</b> <i>Atlantic 1</i>
------------------------	---

**Chair:** Meg Grabb, National Institute of Mental Health

**Co-chair:** Ann Wagner, NIMH/NIH

**Discussant:** Alessandro Bertolino, F. Hoffmann-La Roche Ltd.

3:45pm – 3:50pm	<b>Introduction</b>
-----------------	---------------------

3:50pm – 4:10pm	<b>Measuring Social Disability in Autism Spectrum Disorder</b> Lawrence Scahill, Emory University
-----------------	--

4:10pm – 4:30pm	<b>Honing in on Targets for Compound Selection in ASD Trials: The NIMH FAST-ASD Network</b> James T. McCracken, UCLA Semel Institute
-----------------	---

4:30pm – 4:50pm	<b>Incorporating Potential Functional Biomarkers in Clinical Trials in ASD</b> Bryan H. King, Seattle Children's Hospital and University of Washington
-----------------	---

4:50pm – 5:10pm	<b>Eye-tracking Measures of Social Disability as Outcome Measures in School-age Children with ASD</b> Warren Jones, Marcus Autism Center
-----------------	---

5:10pm – 5:45pm	<b>Discussion</b>
-----------------	-------------------

**3:45pm – 5:45pm****\*Novel Mechanisms of Action for the Treatment of Depression and Anxiety: Scientific Updates  
*Atlantic 2*****Chair:** Timothy Petersen, Clintara, LLC**Co-chair:** Jaskaran Singh, Janssen Research and Development, LLC**Discussant:** Randall D. Marshall, Alkermes**3:45pm – 3:50pm****Introduction****3:50pm – 4:10pm****A Review of Pre-clinical Data**

Gerard Sanacora, Yale University

**4:10pm – 4:30pm****Ketamine: Rationale, Empirical Evidence and New Routes of Delivery**

James W. Murrough, Icahn School of Medicine at Mount Sinai

**4:30pm – 4:50p****Treatment of Suicidality with Novel Mechanisms**

Sanjay Mathew, Baylor College of Medicine

**4:50pm – 5:10pm****The Role of Pherines for Rapid Relief of Depressive and Anxiety Symptoms**

Michael R. Liebowitz, Pherin Pharmaceuticals

**5:10pm – 5:30pm****Novel Developments in Non-invasive Neurostimulation for the Treatment of Mood Disorders**

Dan V. Iosifescu, Icahn School of Medicine at Mount Sinai

**5:30pm – 5:45pm****Discussion***\*of special interest to clinicians*

3:45pm – 5:45pm

**\*Psychiatry and Technology: A Partnership in Promoting Mental Health**  
*Atlantic 3*

**Chair:** Holly A. Swartz, University of Pittsburgh School of Medicine

**Discussant:** Ellen Frank, University of Pittsburgh School of Medicine

3:45pm – 3:50pm

**Introduction**

3:50pm – 4:10pm

**MoodSwings 2.0 for Bipolar Disorder:**

[www.moodswings.net.au](http://www.moodswings.net.au)

Victoria E. Cosgrove, Stanford University School of Medicine

4:10pm – 4:30pm

**MoodRhythm: Pilot Testing a Smartphone App for Monitoring Mood and Daily Routines**

Mark Matthews, Cornell University

4:30pm – 4:50pm

**Using Smartphones to Enhance Skill Acquisition and Utilization in CBT for Child Anxiety**

Jennifer Silk, University of Pittsburgh

4:50pm – 5:10pm

**Computerized Adaptive Testing (CAT) and the Future of Psychiatric Measurement**

Robert Gibbons, University of Chicago

5:10pm – 5:45pm

**Discussion**

*\*of special interest to clinicians*

[illegible]



## AT-A-GLANCE

### Thursday, June 19, 2014

7:30am – 9:00am      **Morning Break**  
Ballroom Foyers

8:30am – 10:00am      **Panel Sessions**

Clinical Trials in Early Stage Alzheimer's Disease: Current Methodological and Regulatory Considerations	The NIMH- Funded RAPID Network Studies	Leveraging the Internet and Social Media to Improve Pathways to Care and Shorten DUP in Schizophrenia	Practical Trials in Psychiatry: The Need, The Opportunities
Location: Diplomat 1-2	Location: Atlantic 1	Location: Atlantic 2	Location: Atlantic 3

10:00am – 10:15am      **Break**  
Ballroom Foyers

10:15am – 11:45am      **Plenary: Regulatory Wrap-up Session**  
Grand Ballroom

12:00pm      **Meeting Adjourns**

[illegible]

## FULL SCHEDULE

### Thursday, June 19, 2014

**7:30am – 9:00am**      **Morning Break**  
*Ballroom Foyers*

### Panel Sessions

**8:30am – 10:00am**      **Clinical Trials in Early Stage Alzheimer's Disease: Current Methodological and Regulatory Considerations**  
*Diplomat 1-2*

**Chair & Discussant:** Kathleen Welsh-Bohmer, Joseph and Kathleen Bryan  
Alzheimer's Disease Research Center

**8:30am – 8:40am**      **Introduction**

**8:40am – 9:00am**      **What Are We Trying to Measure in Preclinical and Prodromal Alzheimer's Disease?**  
Lon S. Schneider, Keck School of Medicine of USC

**9:00am – 9:20am**      **What are the Optimal Cognitive Outcome Measures for Trials in Preclinical Alzheimer's Disease?**  
Keith Wesnes, Bracket Global

**9:20am – 9:40am**      **Drug Development Cognition Challenges**  
Marc Cantillon, Kyowa Hakko Kirin Pharma, Inc.

**9:40am – 10:00am**      **Discussion**

**8:30am – 10:00am      The NIMH-Funded RAPID Network Studies  
*Atlantic 1***

**Chair:** Maurizio Fava, Massachusetts General Hospital

**Co-chair:** Mi Hillefors, NIMH

**Discussant:** Carlos A. Zarate, NIMH

8:30am – 8:40am      **Introduction**

8:40am – 9:00am      **A POC of Low-field Magnetic Stimulation:  
Methodological Issues and Innovations in the  
Implementation of a Novel Device Study in MDD**  
Maurizio Fava, Massachusetts General Hospital

9:00am – 9:20am      **Potential Rapid Antidepressant Augmentation with  
a Selective Kappa Antagonist**  
Sitra Tauscher-Wisniewski, Lilly Research Labs

9:20am – 9:40am      **A Dose-finding Study of I.V. Ketamine in  
Treatment-resistant Depression**  
Gerard Sanacora, Yale University School of Medicine

9:40am – 10:00am      **Discussion**

**8:30am – 10:00am      Leveraging the Internet and Social Media to  
Improve Pathways to Care and Shorten DUP in  
Schizophrenia  
*Atlantic 2***

**Chair:** John M. Kane, The Zucker Hillside Hospital

**Discussant:** Donald C. Goff, NYU Medical School

8:30am – 8:40am      **Introduction**

8:40am – 8:55am      **Duration of Untreated Psychosis and it's  
Correlates in Patients with Schizophrenia-  
spectrum Disorders: Results from a Large Meta-  
analysis of First Episode Studies**  
Christoph Correll, The Zucker Hillside Hospital

8:55am – 9:10am      **Understanding Pathways to Care in Early-course  
Psychotic Disorders**  
Michael T. Compton, Hofstra North Shore-LIJ School  
of Medicine at Hofstra University

<b>8:30am – 10:00am (continued)</b>	<b>Leveraging the Internet and Social Media to Improve Pathways to Care and Shorten DUP in Schizophrenia</b> <i>Atlantic 2</i>
9:10am – 9:25am	<b>Early Detection of Psychosis through Self-report Screening</b> Rachel Loewy, University of California
9:25am – 9:40am	<b>Reducing DUP in the Age of Social Media and the Internet</b> John M. Kane, The Zucker Hillside Hospital
9:40am – 10:00am	<b>Discussion</b>
<b>8:30am – 10:00am</b>	<b>Practical Trials in Psychiatry: The Need, The Opportunities</b> <i>Atlantic 3</i>

**Chair & Discussant:** Benedetto Vitiello, NIMH

**Co-chair:** Nina R. Schooler, SUNY Downstate Medical Center

8:30am – 8:40am	<b>Introduction</b>
8:40am – 8:55am	<b>Practical, Pragmatic, and Possible Psychopharmacology Clinical Trials: Lessons Learned from the AHRQ Bipolar CHOICE study</b> Andrew Nierenberg, Massachusetts General Hospital
8:55am – 9:10am	<b>Expanding the Place of Practice-based Clinical Trials on the Explanatory-pragmatic Spectrum</b> Greg Simon, Group Health Research Institute
9:10am – 9:25am	<b>A Regulatory Perspective on Practical Clinical Trials</b> Thomas Laughren, MGH CTNI
9:25am – 9:40am	<b>PCORI and Practical Trials in Mental Health</b> Grayson Norquist, The University of Mississippi Medical Center
9:40am – 10:00am	<b>Discussion</b>

**10:00am – 10:15am**      **Break**  
*Ballroom Foyers*

**10:15am – 11:45am**      **Plenary: Regulatory Wrap-up Session**  
*Grand Ballroom*

**Chair:** Ni A. Khin, M.D., U.S. Food and Drug Administration

Phillip Kronstein, M.D., Food and Drug Administration  
Celia Winchell, M.D., Food and Drug Administration  
Silvana Borges, M.D., Food and Drug Administration

**12:00pm**                      **Meeting Adjourns**

## Tuesday, June 17, 2014

### Poster Session 1

- P-1 **A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Intravenous Ketamine in Patients with Treatment-Resistant Depression**  
Jaskaran Singh, Janssen Research and Development, LLC
- P-2 **A Pilot Study of a Novel Monoamine Triple Reuptake Inhibitor EB-1020 SR in the Treatment of ADHD in Adults**  
Timothy Wilens, Massachusetts General Hospital  
Andrew J. Cutler, Ann Childress, Randall D. Marshall, Mark Bradshaw, Frank Bymaster, Anthony McKinney, Stephen W. Hurt, Catherine O'Brien, Timothy Hsu
- P-3 **AZD8529, a Positive Allosteric Modulator of the mGluR2 Receptor for the Treatment of Schizophrenia**  
Alan Cross, AstraZeneca Neuroscience Innovative Medicines Unit
- P-4 **Efficacy and Safety of a Novel mGlu2 Receptor Positive Allosteric Modulator as an Adjunctive Treatment to an SSRI/SNRI in the Treatment of Anxious Depression**  
Justine Kent, Janssen  
Ella Daly, Ceusters Marc, Iva Kezic, Rosanne Lane, Lim Pilar, De Smedt Heidi, Mazzucco Christine, Peter DeBoer, Luc Van Nueten, Wayne Drevets
- P-5 **Lupron in Combination with an Acetylcholinesterase Inhibitor Halts Cognitive Decline in Women with Alzheimer 's Disease over a 48 Week Period**  
Richard Bowen, OTB Research  
Craig Atwood
- P-6 **Results of a Phase 28 Clinical Trial of TC-5619, a Selective Alpha 7 Neuronal Nicotinic Receptor (NNR) Agonist in the Adjunctive Treatment of Negative Symptoms and Cognitive Dysfunction in Schizophrenia**  
David Hosford, Targacept, Inc.  
Chris Dvergsten, Jessica Beaver, Anthony Segreti, Steven Toler, Gaston Farr, Melissa Joseph, John Jett, Patrick Lippiello, Merouane Bencherif
- P-7 **A Rapidly Acting Intranasal Treatment for the Symptoms of GAD**  
Michael Liebowitz, Pherin Pharmaceuticals  
Louis Monti, Rita Hanover, Bernard Grosser
- P-8 **Metadoxine Extended Release (MDX): A Novel Drug Candidate for the Treatment of ADHD & Other Cognitive Disorders**  
Jonathan Rubin, Alcobra Pharma  
Yaron Daniely, Lenard Adler

*\*P-# References a Pharmaceutical Pipeline Presentation.*

- 1      **Memantine in the Treatment of Executive Function Deficits in Adults with ADHD: A Pilot Randomized Double Blind Controlled Clinical Trial**  
 Joseph Biederman, Massachusetts General Hospital  
 Ronna Fried, Laura M. Tarko, Craig Surman, Stephen V. Faraone, Thomas Spencer
-  2      **Effects of Lisdexamfetamine Dimesylate on Brain Reward Circuitry in Adults with ADHD**  
 Stephanie Duhoux, Icahn School of Medicine at Mount Sinai  
 Kurt Schulz, Beth Krone, Anne-Claude V. Bédard, Juan D. Pedraza, Lenard Adler, Stuart F. White, James Blair, Jeffrey Newcorn
- 3      **The Methylphenidate-atomoxetine Crossover Study in ADHD Youth: Measuring and Comparing Response**  
 Mark Stein, The University of Washington  
 Tom Hildebrandt, Jeffrey Newcorn
- 4      **The Role of Aldosterone and Cortisol in Alcohol Use Disorders in a Baclofen Treatment Study**  
 Elie G. Aoun, Brown University, Butler Hospital  
 Carolina Haass-Koffler, Robert Swift, Giovanni Addolorato, George Kenna, Lorenzo Leggio
- 5      **Addiction Severity Index Family Composite Scale More Reliable Than Combined Family/Social Composite**  
 Wayne H. Denton, Florida State University  
 Jacob B. Priest, Sarah B. Woods
- 6      **Periodic Placebo Effect in an Addiction Therapy Trial**  
 Bernard L. Silverman, Alkermes, Inc.  
 Jacqueline Zummo, Asli Memisoglu, David Gastfriend, Walter Ling, Evgeny Krupitsky
-  7      **Adrenergic Receptor Modulation for the Treatment and Prevention of Post-traumatic Stress Disorder and Co-morbid Disorders**  
 Chaya G. Bhuvaneshwaran, University of Massachusetts-Worcester
-  8      **An Epigenome-wide Assessment of Atypical Antipsychotic Side Effects in Bipolar Disorder**  
 Kyle J. Burghardt, University of Michigan College of Pharmacy  
 Vicki L. Ellingrod



= New Investigator




- 9      **Biomarkers of Cardiometabolic Risk in Antipsychotic Treated Youth**  
Ginger E. Nicol, Washington University School of Medicine  
Michael D. Yingling, Julia A. Schweiger, John Newcomer
- 10     **Plasma Polyunsaturated Fatty Acid Markers Differ in Symptomatic Bipolar Disorder**  
Erika Saunders, Penn State College of Medicine, Penn State University  
Kaizong Ma, Eric Schaefer, Alan Gelenberg, Stanley Rapoport
- 11     **Reliable Change Index and Clinical Significance in Clinical Trials Using the Positive and Negative Syndrome Scale (PANSS)**  
Mark Opler, ProPhase LLC, New York University School of Medicine  
Anzalee Khan, Linda Gao, Brian Rothman, Luka Lucic
- 12     **Prenatal Stress Evokes Long-term Changes in Brain Glucose Metabolism**  
Boguslawa Budziszewska, Institute of Pharmacology, Polish Academy of Sciences  
Anna Kurek, Jan Detka, Agnieszka Basta-Kaim, Monika Leśkiewicz, Marta Kubera
- 13     **Efficacy and Safety of Treatment with Lurasidone Adjunctive with Lithium or Valproate in Bipolar I Depression: Results of Two 6-week Studies**  
Joseph R. Calabrese, Case Western Reserve School of Medicine  
Trisha Suppes, Kaushik Sarma, Robert Silva, Hans Kroger, Josephine Cucchiaro, Andrei Pikalov, Antony Loebel
- 14     **MoodSwings 2.0 ([www.moodswings.net.au](http://www.moodswings.net.au)): An Online Intervention for Bipolar Disorder**  
Victoria E. Cosgrove, Stanford University School of Medicine  
Trisha Suppes, Sue Lauder, Emma Gliddon, Karishma Raju, Seetal Dodd, E. Grace Fischer, Michael Berk
- 15     **Clinically Relevant Change Using CGI-BP in Patients with Acute Depressive Episodes of Bipolar I or II Disorder in Quetiapine XR Study**  
Catherine Datto, AstraZeneca  
Jason Wright, Scott LaPorte, Michelle Shay

- 16      **Number Needed to Treat for Discontinuation Due to Adverse Events, Somnolence,  $\geq 7\%$  Weight Gain, Extrapyramidal Side Effects, Response, and Remission of Atypical Antipsychotics in Acute Bipolar Depression**  
Kemeng Gao, Case Western Reserve University
- 17      **Lurasidone in Bipolar I Depression: A 24 Week, Open-label Extension Study**  
Terence Ketter, Stanford University School of Medicine  
Kaushik Sarma, Robert Silva, Hans Kroger, Josephine Cucchiaro, Antony Loebel
- 18      **Sleep Patterns across the Bipolar Spectrum: Similarities and Differences between Mood States and Across Diagnostic Subtypes**  
Jessica C. Levenson, University of Pittsburgh  
Holly A. Swartz, Ellen Frank, David J. Kupfer
- 19      **Global Improvement in Bipolar Mania Patients Treated with Cariprazine**  
Robert E. Litman, CBH Health, LLC  
Kaifeng Lu, Krisztián Nagy, István Laszlovszky, Suresh Durgam
- 20      **Psychopharmacology Algorithm for Acute Mania**  
David Osser, Harvard Medical School  
Othman Mohammad
- 21      **The Psychopharmacology Algorithm Project at the Harvard South Shore Program: 2014 Update on Bipolar Depression**  
Dana Wang, Harvard Medical School, VA Boston Healthcare System  
Arash Ansari, David Osser
- 22      **Correlation between Different Levels of Placebo Response Rate and Clinical Trial Outcome in Bipolar Depression**  
George I. Papakostas, Massachusetts General Hospital, Harvard Medical School  
Nadia Iovieno, Rosemary Walker
-  23      **Resilience in High-risk Infants and Toddlers of Mothers with Bipolar Disorder: A Longitudinal Investigation**  
Diana I. Simeonova, Emory University School of Medicine  
Theresa Nguyen, Kerry Ressler, W. Edward Craighead



= New Investigator

- 24 **A Dimensional Assessment of Anxiety and Tic Severity in Tourette's Disorder**  
Barbara Coffey, Icahn School of Medicine at Mount Sinai, Nathan S. Kline Institute for Psychiatric Research  
Vilma Gabbay
-  25 **Computerized Adaptive Diagnosis and Testing in Psychiatric Outpatients Seeking Care at a Large, Free-standing Psychiatric Hospital**  
Eric D. Achtyes, Michigan State University College of Human Medicine  
Scott Halstead, LeAnn D. Smart, Robert D. Gibbons
- 26 **A Dimensional Rating System for Psychiatric Disorders in Psychiatric Outpatients**  
Mark Zimmerman, Rhode Island Hospital
- 27 **A Clinically Useful Self-report Measure of the DSM-5 Anxious Specifier of Major Depressive Disorder**  
Mark Zimmerman, Rhode Island Hospital
- 28 **Reduction of Placebo Response in Depression Trials via Independent Remote (SAFER) Patient Interviews**  
Martina J. Flynn, Massachusetts General Hospital Clinical Trials Network and Institute  
Marlene Freeman, Maurizio Fava, David Mischoulon, James Pooley, Daniel Burch, Heather Bryson
- 29 **A Comparison of Cross-cultural Regional Norms for the MATRICS Consensus Cognitive Battery (MCCB)**  
Richard S. E. Keefe, NeuroCog Trials, Duke University  
Ioan Stroescu, Vicki G. Davis, Alexandra S. Atkins
- 30 **Magnitude of Change with Antidepressants and Placebo in Antidepressant Clinical Trials Using Structured, Taped and Appraised Rater Interviews Compared to Traditional Semi-structured Interviews**  
Arif Khan, Northwest Clinical Research Center  
James Faucett, Walter Brown
- 31 **The Impact of Implementing a National Research Subject Database to Prevent Dual Enrollment in Early and Late Phase Central Nervous System Trials**  
Kerri Weingard, Accumed Research Associates & Verified Clinical Trials  
Mitchell Efros



= New Investigator

- 32     **Early Life Stress as a Risk Factor for Substance Use Disorders: Clinical and Neurobiological Substrates**  
Sajoy Purathumuriyil Varghese, Rosalind Franklin University of Medicine and Science
- 33     **Panic Disorder: Theoretical Overlap with Narcolepsy**  
Thomas W. Uhde, MUSC  
Bernadette M. Cortese, Priyattam Shiromani, Orlena Merritt-Davis, Yury Yaroslavsky, Ravi Singareddy, Kimberly R. Leslie, Martha Strachan, Jennifer Runion, David Bachman, Richard K. Bogan
- 34     **A Five Year Observational Study of Patients with Treatment Resistant Depression Treated with VNS Therapy® or Treatment as Usual: Comparative Response/Remission Rates, Duration of Response, and Quality of Life**  
Scott T. Aaronson, Sheppard Pratt Health System  
Mark T. Bunker, Peter Sears, Francis Ruvuna
- 35     **Prenatal Stress Influences the Proper Functioning of the Primary Microglial Cells and Leads to Behavioral Changes in Adult Offspring - A Link to Depression**  
Agnieszka Basta-Kaim, Institute of Pharmacology, Polish Academy of Sciences  
Joanna Slusarczyk, Bogusława Budziszewska, Monika Le kiewicz, Marta Kubera
- 36     **The Efficacy of Vilazodone in Achieving Remission in Patients with Major Depressive Disorder: Post Hoc Analyses of a Phase IV Trial**  
Leslie Citrome, New York Medical College  
Carl Gommoll, Xiongwen Tang, Rene Nunez, Maju Mathews
- 37     **Clinical Relevance of Levomilnacipran ER Treatment in Patients with Major Depressive Disorder: Improvements in Functional Impairment Categories**  
Andrew J. Cutler, Florida Clinical Research Center, LLC  
Carl Gommoll, Changzheng Chen, William M. Greenberg, Adam Ruth
- 38     **Levomilnacipran Inhibits both Norepinephrine and Serotonin Reuptake across the Clinical Dose Range**  
Tobie Escher, Forest Research Institute  
Joann O'Connor, Laishun Chen, Carl Gommoll, Stephen Zukin


- 39     **Increased ACC and Striatal Total Choline Levels in Adolescent Depression**  
Vilma Gabbay, Icahn School of Medicine at Mount Sinai; Nathan S. Kline Institute for Psychiatric Research  
Ana I. Vallejo, Amy R. Johnson
- 40     **Cognitive Domains Impacted by Vortioxetine Treatment of Patients with Major Depressive Disorder (MDD)**  
John E. Harrison, Metis Cognition Ltd.  
Søren N. Lophaven, Christina Kurre Olsen
- 41     **A Head-to-head, Randomized, Comparison Study of Vortioxetine vs. Escitalopram in Patients Well Treated for MDD and Experiencing Treatment-emergent Sexual Dysfunction**  
Paula L. Jacobsen, Takeda Development Center Americas  
Atul R. Mahableshwarkar, Yinzhong Chen, Lambros Chrones, Anita Clayton
- 42     **The Role of Pro-inflammatory Cytokines in Modulation of Activity of Serotonergic System in Women with Postpartum Depressive Symptoms and in Animal Models of Depression**  
Marta Kubera, Institute of Pharmacology, Polish Academy of Sciences  
Katarzyna Curzytek, Weronika Duda, Joanna Slusarczyk, Monika Leskiewicz, Krystyna Golembiowska, Magdalena Regulska, Agnieszka Basta-Kaim, Bogusława Budziszewska, Wladyslaw Lason, Michael Maes
- 43     **Anti-anhedonic Effect of Ketamine and its Neural Correlates in Major Depressive Disorder**  
Níall Lally, National Institutes of Health  
Allison C. Nugent, David Luckenbaugh, Carlos Zarate
- 44     **ALKS 5461, a Novel Opioid Modulator as Adjunctive Treatment for Depression: Addressing Abuse Potential, Safety and Efficacy**  
Randall D. Marshall, Alkermes, Inc.  
Ryan Turncliff, J. Alexander Bodkin, Lauren E. DiPetrillo, Richard Leigh-Pemberton, Michael E. Thase, Madhukar Trivedi, Asli Memisoglu, Maurizio Fava
- 45     **Effects of Vilazodone on Sexual Dysfunction in Major Depressive Disorder: A Randomized, Double-blind Trial with Placebo and Active Controls**  
Maju Mathews, Forest Research Institute  
Carl Gommoll, Dalei Chen, Rene Nunez

- 46 **A 8-week Randomized, Double-blind Trial Comparing Efficacy, Safety and Tolerability of Three Vilazodone Dose Initiation Strategies Following Switch from SSRIs or SNRIs in Major Depressive Disorder**  
Robert Millet, Duke University  
Shilpa Rele, Sungman Kim, Jong-Woo Paik, Seonghwan Kim, Varun Kasula, Prakash Masand, Ashwin Patkar
- 47 **Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and a History of Inadequate Response to Antidepressants: Post-hoc Analyses of a Randomized, Placebo Controlled Study (PURSUIT)**  
Sanjeev Pathak, AstraZeneca  
Hong-Lin Su, Joel Posener, Khanh Bui, Michael Quirk, Tim Piser, Sanjay Mathew, Gerard Sanacora
- 48 **The Rosenberg Hassman Mood Scale - An Update on the Development of This Depression Rating Scale with Feedback from 50 Patients**  
Leon I. Rosenberg, Center for Emotional Fitness  
Keith Wesnes, Sanju George, Howard Hassman, Mary Gelovich
- 49 **Efficacy of Vortioxetine vs. Placebo in Adults with Major Depressive Disorder (MDD): Meta-analyses of MADRS Single Items from 9 Short-term Studies**  
Michael E. Thase, Perelman School of Medicine of the University of Pennsylvania  
Atul R. Mahableshwarkar, Henrik Loft, Marianne Dragheim
- 50 **mTOR Signaling Correlates with Treatment Response to Ketamine in a Preclinical Model of Treatment Resistant Depression**  
Susannah J. Tye, Mayo Clinic  
Adam Walker, Blair Price, Chunling Hu, Shari Sutor, Mark A. Frye
- 51 **A Novel Trial Design to Assess Rapid and Sustained Antidepressant Effects of an Oral NR2B Specific NMDA Receptor Antagonist, CERC-301**  
James Vornov, Cerecor, Inc.  
Maurizio Fava, Michael Detke, Chao Wang, Larry Ereshefsky, Richard C. Shelton, Michael E. Thase, Madhukar Trivedi

- 52     **An International Study of the GRID-HAMD: Has It Fulfilled Its Promise?**  
Janet Williams, MedAvante, Inc.  
Matej Ondrus, Melanie Rishton, Jennie K. Persson, Marlene Popescu,  
Risto Valjakka
- 53     **Validation of the Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating to Support Use in Clinical Trials as a Measure of Treatment Benefit**  
Linda Deal, Shire Development LLC  
Robert Wirth, Barry Herman, Maria Gasior, Susan McElroy
- 54     **Acquired Binge-eating Behaviour Produces Alterations in Dopaminergic Neurochemistry in the Brains of Rats**  
Peter Hutson, Shire  
Jane Gosden, Mike Prow, David J. Heal, Sharon Cheetham
- 55     **Definitive Verification and Monitoring of Oral Medication Adherence Using Breath Analysis**  
Donn M. Dennis, Xhale SMART, Inc.  
Eileen Loskie
- 56     **Predictors of Pharmacological Treatment Response in Grooming Disorders**  
Brian L. Odlaug, University of Copenhagen  
Jon E. Grant, Eric Leppink, Katherine L. Derbyshire
- 57     **Web-based Curriculums for Teaching Psychopharmacology: Revision of the Resident and the Medical Student Curriculums**  
Ira Glick, Stanford University School of Medicine
- 58     **The Effects of Social Support on Suicidality in an Adult Inpatient Psychiatric Population as Assessed by the C-SSRS and S-STS**  
Ahmad Hameed, Penn State College of Medicine  
Amanda M. White, Michael Mitchell, Eric A. Youngstrom, Roger E. Meyer, Alan J. Gelenberg
- 59     **Deconstructing Drug Company Promotion: Pursuing Truth: Slides for a 1 Hour Lecture in a Psychopharmacology Course**  
Jeffrey Mattes, Psychopharmacology Research Association of Princeton

- 60 **Metabotropic Glutamate Receptor 7 (GRM7) Pharmacogenetics in First Episode Psychosis**  
James M. Stevenson, University of Illinois College of Pharmacy  
James L. Reilly, Margret S. H. Harris, Konasale M. Prasad, Judith A. Badner, Vishwajit Nimgaonkar, Matcheri S. Keshavan, John A. Sweeney, Jeffrey R. Bishop
- 61 **Medical Informatics in Psychiatric Practice: Current Status and Unmet Needs**  
Farifteh Duffy, American Psychiatric Association/American Psychiatric Foundation  
Laura Fochtmann, Robert M. Plovnick, Diana E. Clarke, Eve K. Mościcki, William Narrow
- 62 **All-cause Discontinuation and Safety of Aripiprazole Once-monthly for the Treatment of Schizophrenia: A Pooled Analysis of Two Double-blind, Randomized, Controlled Trials**  
Ross A. Baker, Otsuka Pharmaceutical Development & Commercialization, Inc.  
W. Wolfgang Fleischhacker, Raymond Sanchez, Lan-Feng Tsai, Timothy Peters-Strickland, Anna Eramo, John Kane
- 63 **Subject Recruitment Strategies: A New Cross-functional Team Approach**  
Kim Cheshire-Kinney, Janssen Research & Development, LLC  
Stephen Rodriguez, James O'Neill, Lucy Mahalchick, Allen Wu
- 64 **Accelerated Aging in Severe Mental Illness Using Levels of Advanced Glycated Endproducts as Indicator. Research Findings and Clinical Consequences**  
Dan Cohen, Mental Health Organization North-Holland North  
Annet Nugter, Andries Smit
- 65 **A Double-blind, Placebo-controlled, Randomized Withdrawal Study of Lurasidone for the Maintenance of Efficacy in Patients with Schizophrenia**  
Josephine Cucchiaro, Sunovion Pharmaceuticals, Inc.  
Rajiv Tandon, Antony Loebel, Debra Phillips, David Hernandez, Yongcai Mao, Andrei Pikalov
- 66 **Categorical Improvements in Disease Severity in Schizophrenia Patients Treated with Cariprazine**  
Suresh Durgam, Forest Research Institute  
Stephen Zukin, Kaifeng Lu, Marc Debelle, István Laszlovszky, Stephen Volk



- 67 **Efficacy and Safety of Aripiprazole Once-monthly in Obese and Non-obese Patients with Schizophrenia: A Post Hoc Analysis**  
Anna Eramo, H. Lundbeck A/S  
Marc De Hert, Wally Landsberg, Lan-Feng Tsai, Ross A. Baker
-  68 **The Effects of Caloric Vestibular Stimulation on Illness Awareness in Schizophrenia: A Pilot, Proof of Concept Study**  
Philip Gerretsen, Centre for Addiction and Mental Health  
David D. Pothier
- 69 **Comparative Outcomes after Switching from Risperidone Long-acting Injectable to Paliperidone Long-acting Injectable or Oral Antipsychotics**  
David Hough, Janssen Research & Development  
Erica Voss, Larry Alphs, Patrick Ryan, Paul Stang
- 70 **Exploring Neuropathological Deficits and New Drug Targets for Major Psychiatric Disorders Using the Stanley Neuropathology Consortium Datasets and RNA-Seq Data**  
Sanghyeon Kim, Stanley Medical Research Institute
- 71 **Clozapine May Exert Its Superior Efficacy on Schizophrenia through Its Serotonin 5HT<sub>2C</sub> Receptor Inverse-agonism**  
Sanghyeon Kim, Stanley Medical Research Institute
- 72 **An Open-label Extension Study of Lurasidone Safety and Efficacy in Patients with Schizophrenia Previously Randomized to Lurasidone or Risperidone**  
Andrei Pikalov, Sunovion Pharmaceuticals, Inc.  
Gregory Mattingly, Michael Tocco, Debra Phillips, Jane Xu, Antony Loebel
- 73 **Correlates of Social Cognition and Neurocognition to Functional Outcomes**  
Brian Rothman, ProPhase, LLC  
Jean-Pierre Lindenmayer, Anzalee Khan, Mark Opler, Linda Gao
- 74 **A Randomized Blind Parallel Intramuscular Haloperidol-controlled Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Intramuscular Levosulpiride in the Treatment of Chinese Patients with Agitation of Schizophrenia**  
Yifeng Shen, Shanghai Mental Health Center  
Huafang Li



= New Investigator

- 75     **Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: Results of a Double-blind Placebo Controlled Study**  
Robert C. Smith, NYU School of Medicine and Nathan Kline Institute for Psychiatric Research
- 76     **Paliperidone Research in Demonstrating Effectiveness (PRIDE): Managing Schizophrenia Patients with a History of Incarceration**  
H. Lynn Starr, Janssen Scientific Affairs, LLC  
Larry Alphs, Lian Mao, Stephen Rodriguez
- 77     **A Randomized, Placebo-controlled Repeat-dose Thorough QT Study of Inhaled Loxapine in Healthy Volunteers**  
Paul P. Yeung, Teva Pharmaceuticals  
James V. Cassella, Daniel A. Spyker
- 78     **Lamotrigine: Are We Dosing it Optimally in Pregnant Women with Bipolar Disorder?**  
Crystal T. Clark, Northwestern University Feinberg School of Medicine
- 79     **Sexual Symptoms Associated with Leuprolide Acetate Therapy in Infertility Patients Treated for Endometriosis**  
Julia “Jill” K. Warnock, University of Oklahoma-HSC- Tulsa  
J. Clark Bundren

## Wednesday, June 18, 2014

### Poster Session 2

- 1     **A Novel Computer-prompted Tandem Rating Assessment for Adult ADHD Clinical Trials**  
Joan Busner, Penn State College of Medicine and Bracket  
Andrew J. Cutler, Gary S. Sachs, Dan DeBonis, Timothy Hsu,  
Catherine O'Brien, Timothy Wilens
  
- 2     **Emotional Dysregulation as an Adult ADHD Subtype**  
Frederick W. Reimherr, Psychiatric & Behavioral Solutions, University  
of Utah  
Tammy A. Steans, Kathleen Reimherr, Phillip D. Gale, Thomas Gift,  
Paul H. Wender, Barrie K. Marchant
  
- 3     **Emotion Recognition Deficits in Treated and Untreated Adult ADHD Patients**  
Anneka Tomlinson, University of Manchester  
Robert Baskind, Joe Johnson, Kay Marshall, Joanna C. Neill
  
- 4     **Attenuation of Ethanol Withdrawal by Ceftriaxone-induced Upregulation of Glutamate Transporter EAAT2**  
Ulas M. Camsari, Mayo Clinic  
Osama Abulseoud
  
- 5     **A Double-blind, Placebo-controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence**  
Raye Z. Litten, NIAAA  
Joanne B. Fertig, Daniel E. Falk, Megan L. Ryan
  
- 6     **Progesterone Treatment for Postpartum Cocaine Users**  
Kimberly Yonkers, Yale School of Medicine  
Mehmet Sofuoglu, Kathleen Carroll
  
- 7     **Desvenlafaxine ER vs. Placebo in Social Anxiety Disorder**  
Michael R. Liebowitz, Pherin Pharmaceuticals  
Ester Salman, Ann E. Johnson, Rita Hanover
  
- 8     **The Predictive Value of Gene Variants Used to Guide Antidepressant Selection**  
Kevin M. Furmaga, Pine Rest CMHS and Michigan State University  
College of Human Medicine (Psychiatry)  
Andrew C. Rose, LeAnn D. Smart, Alan T. Davis, Eric D. Achtyes

- 9      **Determining Pharmacological Selectivity of the Kappa Opioid Receptor Antagonist LY2456302 Using Translational Rat to Human Pupillometry Studies**  
 Linda Rorick-Kehn, Lilly Research Laboratories, Eli Lilly and Co
- 10     **A Naturalistic Study of the Clinical Utility of Pharmacogenetic Testing in Psychiatric Patients**  
 Rachel Scott, Genomind  
 Herbert Harris, Kathryn Gardner, Jay Lombard, Francis X. Brennan
- 11     **How Cardinal are Cardinal Symptoms in Pediatric Bipolar Disorder? A Familial Risk Analysis**  
 Joseph Biederman, Massachusetts General Hospital  
 Stephen V. Faraone, Laura M. Tarko, Mariely Hernandez, Janet Wozniak
- 12     **High EPA Omega-3 Fatty Acids and Inositol as Monotherapy and in Combination in the Treatment of Pediatric Bipolar Disorder: A Pilot Double-blind Randomized Clinical Trial**  
 Joseph Biederman, Massachusetts General Hospital  
 Stephen V. Faraone, Laura M. Tarko, Mariely Hernandez, Janet Wozniak
- 13     **Identifying Patients Meeting the DSM-5 Criteria for Bipolar Disorder Episodes with Mixed Features in Bipolar Disorder Studies with Quetiapine XR**  
 Catherine Datto, AstraZeneca  
 Jason Wright, Scott LaPorte, Michelle Shay
- 14     **Lurasidone Monotherapy for Bipolar Depression: Influence of Baseline Thyroid Function on Treatment Response**  
 Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai  
 Andrei Pikalov, Kei Watabe, Antony Loebel
- 15     **Screening and Validation of Novel Kinase Signaling Pathways for Neuronal Excitability**  
 Wei-Chun Hsu, University of Texas Medical Branch at Galveston  
 Miroslav Nenov, Alexander Shavkunov, Neli Panova-Elektronova, Fernanda Laezza
- 16     **Mediators of Effects of Lurasidone on Functioning and Quality of Life: Results from a Randomized, Double-blind, Placebo-controlled Trial in Patients with Bipolar I Depression**  
 Terence Ketter, Stanford University School of Medicine  
 Cynthia Siu, Krithika Rajagopalan, Andrei Pikalov, Antony Loebel

- 17     **Predictors of Improvement in Quality of Life Associated with Lurasidone Treatment of Bipolar I Depression: Results from a 6-month Continuation Study**  
Terence Ketter, Stanford University School of Medicine  
Cynthia Siu, Mariam Hassan, Krithika Rajagopalan, Andrei Pikalov, Antony Loebel
  
- 18     **Baseline Patient Characteristics of Bipolar II Compared to Bipolar I Disorder in Trials of Acute Bipolar Depression**  
Jamie Mullen, AstraZeneca  
Catherine Datto, Louisa Feeley, Scott LaPorte
  
-  19     **Neural Correlates of Social Stress in Youth with Bipolar Disorder**  
Donna Roybal, University of Texas Health Sciences Center at San Antonio  
Amy Garrett, Victoria E. Cosgrove, Spencer Boucher, Jennifer Pearlstein, Paige Staudenmaier, Jade Garneau-Fournier, Amy Parkinson, Kiki Chang
  
- 20     **The Young Mania Rating Scale in Bipolar Disorder: Evaluation of Sleep and Rater Training**  
Jan Sedway, inVentiv Health Clinical  
Cristina Maneru, Sandor Palfi
  
- 21     **Factors Influencing the Diagnosis and Treatment of Bipolar Depression: A Healthcare Professional Perspective**  
Purvi K. Smith, Health and Wellness Partners  
Andrei Pikalov, Gary S. Sachs, Jani Hegarty
  
-  22     **Sequence Analysis of Drug Target Genes with Suicide Severity in Bipolar Disorder**  
Clement Zai, Centre for Addiction and Mental Health, University of Toronto  
Vanessa Goncalves, Vincenzo De Luca, Arun K. Tiwari, John B. Vincent, James Kennedy
  
- 23     **Immunological Stress Responsivity as a Potential Risk Factor in Pediatric Mood Disorders**  
Victoria E. Cosgrove, Stanford University School of Medicine  
Staudenmaier Paige, Jennifer Pearlstein, Sherrie Li, Kiki Chang



= New Investigator

- 24      **Inter-rater Reliability of the Scales for Outcomes of Parkinson's Disease – Cognition (SCOPA-COG) in MODERATO: A Randomized, Placebo-controlled Trial to Assess the Effect of Rasagiline on Mild Cognitive Impairment in PD Patients**  
Kari Nations, INC Research  
Robin C. Hilsabeck, Russell Tanenbaum, ElizaBeth Grubb, Azhar Choudhry
- 25      **Risk-based Monitoring for Aberrant Rating Patterns and Patient Selection Anomalies in Global Schizophrenia Trials**  
David Daniel, Bracket Global, LLC  
Alan Kott
- 26      **Feasibility, Integrity and Efficiency of the Sequential Parallel Comparison Clinical Trial Design**  
Marc de Somer, Alkermes, Inc.  
Yangchun Du, Asli Memisoglu, Randall D. Marshall, Richard Leigh-Pemberton, Bernard L. Silverman, Elliot Ehrich, Maurizio Fava
- 27      **Blinded Dual Ratings Confirm Primary Site-based Ratings in an MDD Trial**  
Richard Leigh-Pemberton, Alkermes, Inc.  
Asli Memisoglu, Steven D. Targum, J Cara Pendergrass, Philip Rauh, Randall D. Marshall, Bernard L. Silverman, Marc de Somer, Elliot Ehrich
- 28      **Complexity in Protocol Design: Does It Lead to Better Clinical Trial Outcomes?**  
Robert Molpus, CNS Healthcare  
Patricia Brown, Rebecca Hummel, Mark Joyce, Linda Harper, Terri Wood, Angela Menosky, John D. Ehrhardt, Ruth Hummel
- 29      **Impact of BPRS Interview Length on Ratings Precision during a Schizophrenia Trial**  
Steven D. Targum, Clintara, LLC  
J. Cara Pendergrass, Laura Zumpano, Philip Rauh, Nicholas DeMartinis
- 30      **Attenuation of Impulsivity in Bipolar Alcoholics Who Reduce Heavy Drinking: Prospective Evidence from a Randomized Placebo-controlled Trial**  
Bryan Tolliver, Medical University of South Carolina  
James J. Prisciandaro, Delisa Brown, Helena Brenner

- 31 **Efficacy of Quetiapine-XR Monotherapy or Adjunctive Therapy to Antidepressant in Acute Major Depressive Disorder with Generalized Anxiety Disorder: A Randomize, Placebo-controlled Pilot Study**

Keming Gao, Case Western Reserve University



- 32 **Does Algorithm-based Depression Care Mitigate Cognitive Decline in Older Adult Outpatients?**

Aaron M. Koenig, Western Psychiatric Institute & Clinic

Meryl A. Butters, Charles F. Reynolds

- 33 **Pro-cognitive Effects of Ketamine and Underlying Neurocircuitry in Subjects with MDD as Assessed by fMRI and Neuropsychological Testing**

Lynnette A. Averill, Yale School of Medicine, National Center for PTSD

- 34 **Confirming MDDScore as an Aid in the Diagnosis of Major Depressive Disorder**

John A. Bilello, Ridge Diagnostics, Inc.

Linda M. Thurmond, Katie Smith, Robert A. Rubin, Suzin M.

Wright, Floyd Taub, Michael E. Henry, Richard C. Shelton, George I.

Papakostas

- 35 **The Effect of Vortioxetine on Sexual Dysfunction during the Treatment of Adults with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD)**

Anita H. Clayton, University of Virginia

Paula L. Jacobsen, Atul R. Mahableshwarkar, William Palo, Yinzhong

Chen, Marianne Dragheim

- 36 **The Effects of Buprenorphine and Samidorphan, Alone and in Combination, on Monoamine Release within the Nucleus Accumbens Shell and Medial Prefrontal Cortex of Male Wistar Rats**

Daniel Deaver, Alkermes, Inc.

Jacobi I. Cunningham, Mark S. Todtenkopf, Reginald L. Dean, David

Eyeraman



- 37 **The Neurocircuitry of Increased Inflammation in Depression: Preliminary Findings**

Jennifer C. Felger, Emory University School of Medicine

Zhihao Li, Ebrahim Haroon, Bobbi Woolwine, Andrew H. Miller



= New Investigator

- 38     **Anhedonia and Irritability as Correlates of Adverse Clinical Features in Adolescent Major Depression**  
Vilma Gabbay, Icahn School of Medicine at Mount Sinai, Nathan S. Kline Institute for Psychiatric Research  
Amy R. Johnson, Ana I. Vallejo, Amira Hanna
- 39     **A Dual-probe Microdialysis Investigation of the Interaction Between Lisdexamfetamine Dimesylate (LDX) and S-citalopram on CNS Monoamines – Evidence for Synergistic Augmentation of Serotonin and Dopamine Efflux**  
Peter Hutson, Shire  
David Heal, Helen L. Rowley, Rajiv S. Kulkarni
- 40     **Determination of the Monoaminergic Interactions between Lisdexamfetamine Dimesylate (LDX) and Duloxetine Reveals a Synergistic Augmentation of Dopamine Efflux in the Nucleus Accumbens and Striatum**  
Peter Hutson, Shire  
Helen L. Rowley, Rajiv Kulkarni, David J. Heal
- 41     **Safety and Tolerability of Vortioxetine 15 and 20 mg in Subjects with Major Depressive Disorder (MDD): A Phase 3, Long-term, Open-label Extension Study**  
Paula L. Jacobsen, Takeda Development Center Americas, Inc.  
Linda Harper, Michael Serenko, Serena Chan, Atul R. Mahableshwarkar
- 42     **Efficacy and Safety of Vilazodone 20 Mg and 40 Mg in Major Depressive Disorder: A Randomized, Double-blind, Placebo- and Active-controlled Trial**  
Arif Khan, Northwest Clinical Research Center  
Carl Gommoll, Maju Mathews, Dalei Chen, Rene Nunez
- 43     **Optimizing the Response to TMS in Major Depression through Intensive Concomitant Medication Management**  
Kimberly M. Lavigne, Louisiana State University  
James G. Barbee, Tonya C. Hansel, Joshua F. Jansen, Jose Calderon-Abbo
- 44     **Edivoxetine as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment: 3 Randomized, Placebo-controlled, Double-blind Studies**  
James M. Martinez, Eli Lilly and Company  
Susan G. Ball, Lauren B. Marangell, Margaret B. Ferguson, Beth A. Pangallo, Mary Anne Dellva, Celine Goldberger



- 45 **Effects of Vilazodone on Sexual Dysfunction in Major Depressive Disorder: A Randomized, Double-blind Trial with Placebo and Active Controls**

Maju Mathews, Forest Research Institute  
Carl Gommoll, Dalei Chen, Rene Nunez



- 46 **Do the Dissociative Side Effects of Ketamine Mediate Its Antidepressant Effects?**

Mark J. Niciu, National Institutes of Health, National Institute of Mental Health

David Luckenbaugh, Dawn F. Ionescu, Neal Nolan, Erica M. Richards, Nancy Brutsche, Sara Guevara, Carlos Zarate

- 47 **In MDD Patients Switched After an Inadequate Response, the Efficacy and Tolerability of Vortioxetine versus Agomelatine is Independent of Previous Antidepressant Treatment**

George I. Papakostas, Massachusetts General Hospital, Harvard Medical School

Rebecca Z. Nielsen, Marianne Dragheim

- 48 **Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and a History of Inadequate Response to Antidepressants: Primary Results from a Randomized, Placebo-controlled Study (PURSUIT)**

Gerard Sanacora, Yale University School of Medicine

Michael Johnson, Arif Khan, Sarah D. Atkinson, Robert Riesenber, Juan Schronen, Michael A. Burke, John Zajecka, Hong-Lin Su, Sanjay Mathew, Sanjeev Pathak



- 49 **Impact of a Culturally-focused Psychiatric Consultation on Depressive Symptoms among Spanish- and English-speaking Latinos in Primary Care**

Nhi-Ha Trinh, Depression Clinical and Research Program, Massachusetts General Hospital

Ilana Huz, Lara Traeger, Trina Chang, Maurizio Fava, Albert Yeung, Stephen Gilman

- 50 **Association between Physicians' Expectations and Clinical Response: Re-analysis of Data from the Hypericum Depression Trial Study Group**

Sagar A. Vijapura, Harvard Medical School

Justin Chen, George I. Papakostas, Lee Baer, Alisabet Clain, Maurizio Fava, David Mischoulon



= New Investigator

- 51     **A Case Mix Severity Index for Depression**  
Mark Zimmerman, Rhode Island Hospital
- 52     **How Many Different Ways Do Patients Meet the Diagnostic Criteria for Major Depressive Disorder?**  
Mark Zimmerman, Rhode Island Hospital
- 53     **Randomized Controlled Safety and Efficacy Trials of Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder**  
Susan McElroy, University of Cincinnati College of Medicine  
James Hudson, M. Celeste Ferreira-Cornwell, Jana Radewonuk, Maria Gasior
- 54     **Prazosin for Nightmares in Patients with Eating Disorders: A Case Series**  
Padmapriya Musunuri, Einstein Medical Center  
Gibson T. George, Richard Jaffe
- 55     **Effects of Scopolamine on Working Memory Task and Resting Functional Connectivity Using fMRI in Healthy Korean Subjects**  
Brett A. English, PAREXEL International  
Niki Osimo, Alex Korb, Adam Bazih, Lev Gertsik, Larry Ereshefsky
- 56     **Improving Psychopharmacology Education and Practice: The Quandary of Getting Data and Information to the Teachers**  
Ira Glick, Stanford University School of Medicine  
Richard Balon, Sidney Zisook
- 57     **Is Pain a Risk Factor for Suicidality as Assessed by the C-SSRS and S-STIS? Findings from an Adult Inpatient Psychiatric Sample**  
Ahmad Hameed, Penn State College of Medicine  
Amanda M. White, Michael Mitchell, Eric A. Youngstrom, Roger E. Meyer, Alan J. Gelenberg
- 58     **A Prospective Open-label Trial of Memantine Hydrochloride for the Treatment of Core Features of Autism Spectrum Disorder in High-functioning Adults**  
Gagan Joshi, Massachusetts General Hospital/Harvard Medical School  
Janet Wozniak, Ronna Fried, Laura Tarko, Stephannie L. Furtak, Leah Feinberg, Joseph Biederman

- 59     **The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males**  
 Erin McGlade, University of Utah Brain Institute, University of Utah Department of Psychiatry  
 Allison Locatelli, Jennifer DiMuzio, Miho Kizaki, Eri Nakazaki, Toshikazu Kamiya, Deborah Yurgelun-Todd
- 60     **Evaluation of the Implementation of Psychotropic Medication Utilization Parameters for Children and Adolescents in Texas Foster Care**  
 M. Lynn Crismon, The University of Texas at Austin  
 James A. Rogers, Alan Shafer, Nina J. Muse
- 61     **How to Collaborate with CRA, from a China Clinical Site Perspective**  
 Yifeng Shen, Shanghai Mental Health Center  
 Huafang Li
- 62     **Tolerability and Safety Profile of Aripiprazole Once-monthly in the Treatment of Schizophrenia: A Pooled Analysis from the Safety Database of 11 Completed or Ongoing Trials**  
 Ross A. Baker, Otsuka Pharmaceutical Development & Commercialization, Inc.  
 Peter Hertel, Anna-Greta Nylander, Na Jin, Anna Eramo, Ruth Duffy, Robert D. McQuade, Timothy Peters-Strickland
- 63     **Leucocytes Point of Care Measurement in Clozapine Therapy**  
 Dan Cohen, Mental Health Organization North-Holland  
 Jan Bogers
- 64     **Early Improvement Predicts Endpoint Response to Lurasidone in Schizophrenia: Pooled Analysis of Five Double-blind Trials**  
 Christoph Correll, Hofstra North Shore-LIJ School of Medicine in New York  
 Andrei Pikalov, Jay Hsu, Josephine Cucchiaro, Robert Goldman, Antony Loebel
- 65     **Safety and Tolerability of Cariprazine in Long-term Treatment of Schizophrenia: Integrated Summary of Safety Data**  
 Andrew J. Cutler, Florida Clinical Research Center, LLC  
 Henry A. Nasrallah, Yao Wang, Kaifeng Lu, Krisztián Nagy, István Laszlovszky, Suresh Durgam

- 66 **The Effect of Previous Dose of Oral Aripiprazole (10 or 30 Mg/Day) on the Efficacy and Tolerability of Aripiprazole Once-monthly: Post-hoc Analyses of Two Double-blind, Randomized, Controlled Trials**  
 Anna Eramo, H. Lundbeck A/S  
 Ross A. Baker, Anna-Greta Nylander, Lan-Feng Tsai, Timothy Peters-Strickland, Raymond Sanchez
- 67 **Paliperidone Palmitate Delays Relapse and Maintains Functioning in Patients with Stabilized Psychotic and Mood Symptoms of Schizoaffective Disorder**  
 Dong-Jing Fu, Janssen Scientific Affairs, LLC  
 Larry Alphs, Jean-Pierre Lindenmayer, Nina R Schooler, Richard B. Simonson, Ibrahim Turkoz, David P. Walling
- 68 **Eszopiclone for Insomnia Treatment in Clinically Stable Patients with Schizophrenia: A Double-blind, Randomized, Placebo-controlled Trial**  
 Sinan Guloksuz, Yale University School of Medicine  
 Cenk Tek, Laura Palmese, Andrew Krystal, Pamela DeGeorge, Erin Reutenauer
- 69 **Virtual Reality Functional Capacity Assessment: Progress on the Validation of a Computerized Assessment of Functional Skills**  
 Richard S.E. Keefe, NeuroCog Trials, Duke University  
 Stacy Ruse, Vicki G. Davis, Alexandra S. Atkins, Thomas L. Patterson, Meera Narasimhan, Philip Harvey
- 70 **Effect of Long-term Treatment with Lurasidone or Risperidone on Metabolic Syndrome Status in Patients with Schizophrenia**  
 John Newcomer, Florida Atlantic University  
 Andrei Pikalov, Kei Watabe, Josephine Cucchiaro, Krithika Rajagopalan, Antony Loebel
- 71 **Aripiprazole Once-monthly for Long-term Maintenance Treatment of Schizophrenia: A 52-week Open-label Study**  
 Timothy Peters-Strickland, Otsuka Pharmaceutical Development & Commercialization, Inc.  
 Ross A. Baker, Robert D. McQuade, Anna Eramo, Pamela P. Perry, Brian R. Johnson, Raymond Sanchez, Anna R. Duca

- 72     **Psychometric Properties of the Dynamic Social Cognition Battery (DSCB), a Comprehensive Toolkit for Social Cognition in Patients with Schizophrenia**  
Brian Rothman, ProPhase LLC  
Anzalee Khan, Luka Lucic, Linda Gao, Mark Opler
- 73     **Prevalence, Healthcare Utilization, and Cost of Patients Dual Diagnosed with Schizophrenia and an Alcohol Use Disorder**  
Bernard L. Silverman, Alkermes, Inc.  
Jacqueline Zummo, Lauren E. DiPetrillo, Cathy Garabedian
- 74     **Insight into Illness and Uncooperativeness in Chronic Schizophrenia**  
Cynthia Siu, Data Power  
Ofer Agid, Mary Waye, Gary Remington, Philip Harvey
- 75     **Safety and Efficacy of Aripiprazole Lauroxil: Results from a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study in Subjects with Acute Exacerbation of Schizophrenia**  
Srdjan R. Stankovic, Alkermes, Inc.  
Robert Risinger, Yangchun Du, Jacqueline Zummo, Lisa Corey, Bernard L. Silverman, Elliot Ehrich
- 76     **How Does the NSA-4 Compare to the NSA-16?**  
Janet Williams, MedAvante, Inc.  
Lori M. Garzio, Doug Osman, Danielle Popp
- 77     **Inhaled Loxapine and Intramuscular Lorazepam in Healthy Volunteers: A Randomized, Placebo-controlled Drug-drug Interaction Study**  
Paul P. Yeung, Teva Pharmaceuticals  
Daniel A. Spyker, James V. Cassella, Randall R. Stoltz
- 78     **Validity Characteristics of the Cognitive Assessment Interview (CAI) in Stable Outpatients with Schizophrenia**  
Robert Goldman, Sunovion Pharmaceuticals, Inc.  
Joseph Ventura, Cynthia Siu, Antony Loebel
- 79     **The National Pregnancy Registry for Atypical Antipsychotics: Effects of Fetal Exposure on Risk for Major Malformations and Extrapyramidal Symptoms**  
Lee S. Cohen, Massachusetts General Hospital  
Adele C. Viguera, Kathryn McInerney, Molly Kwiatkowski, Shannon Murphy, Elizabeth Lemon, Sonia Hernandez-Diaz

- 80     **Raving and Depression in Opiate Dependent Mentally Ill Receiving Suboxone and Group CBT Therapy**  
Tanya Alim, Howard University  
Leslie Adams, Didier Grandjean, Steven Tulin, Elizabeth Carpenter-Song, Moria Hipolito, Loretta D. Peterson, William B. Lawson
- 81     **Efficacy and Safety of ABT-126 as a  $\alpha 7$  Nicotinic Cholinergic Agonist, in Treatment of Cognitive Impairment Associated with Schizophrenia: Results from a Proof Concept Study**  
George Haig, AbbVie, Inc.  
Jeff Baker, Weining Robieson, Earle Bain, Ahmed A. Othman

Aaronson, Scott T.	74	Boucher, Spencer	83
Abulseoud, Osama	81	Bowen, Richard	35, 69
Achtyes, Eric	26, 73, 81	Bradshaw, Mark	69
Adams, Leslie	92	Brennan, Francis X.	82
Addolorato, Giovanni	70	Brenner, Helena	84
Adler, Lenard	70	Briggs, Josephine	13, 57
Agid, Ofer	91	Brimijoin, Stephen	31
Alim, Tanya	92	Broich, Karl	16
Alpert, Jonathan	51	Brown, Delisa	84
Alphs, Larry	79, 80, 90	Brown, Patricia	84
Altemus, Margaret	34	Brown, Walter	36, 73
Andreazza, Ana	26, 49	Brutsche, Nancy	87
Ansari, Arash	72	Bryan, Joseph and Kathleen	65
Anton, Raymond F.	32	Bryson, Heather	73
Aoun, Elie G.	70	Budziszewska, Bogusława	71, 74, 75
Atkins, Alexandra S.	73, 90	Bui, Khanh	76
Atkinson, Sarah D.	87	Bundren, J. Clark	80
Atwood, Craig	69	Bunker, Mark	25, 74
Austin, Christopher	12, 57	Burch, Daniel	73
Averill, Lynnette A.	85	Burdick, Katherine	33, 49
Bachman, David	74	Burghardt, Kyle	26, 70
Badner, Judith A.	78	Burke, Michael A.	87
Baer, Lee	87	Busner, Joan	81
Bain, Earle	92	Butters, Meryl A.	85
Baker, Jeff	92	Bymaster, Frank	69
Baker, Ross A.	78, 79, 89, 90	Calabrese, Joseph R.	33, 71
Baldwin, David	48	Calarge, Chadi	50
Ball, Susan G.	86	Calderon-Abbo, Jose	86
Balon, Richard	88	Camprodon, Joan	26, 48
Barbee, James G.	86	Camsari, Ulas M.	81
Baskind, Robert	81	Cantillon, Marc	65
Basta-Kaim, Agnieszka	71, 74, 75	Caroff, Stanley N.	29
Bazih, Adam	88	Carpenter-Song, Elizabeth	92
Beaver, Jessica	69	Carroll, Kathleen	81
Bédard, Anne-Claude V.	70	Cassella, James V.	80, 91
Bencherif, Merouane	69	Chan, Serena	86
Ben-Zee, Dror	39	Chang, Kiki	83
Berk, Michael	71	Chang, Trina	87
Bertolino, Alessandro	59	Cheetham, S.	77
Bhuvaneswaran, Chaya	26, 70	Chen, Changzheng	74
Biederman, Joseph	70, 82, 88	Chen, Dalei	75, 86, 87
Bilello, John A.	85	Chen, Justin	87
Bishop, Jeffrey R.	78	Chen, Laishun	74
Blair, James	70	Chen, Yinzong	85
Bodkin, J. Alexander	75	Chengappa, Roy K.N.	49
Bogan, Richard K.	74	Chen, Yinzhang	75
Bogers, Jan	89	Cheshire-Kinney, Kim	78
Borgess, Silvana	8, 14, 43, 68	Childress, Ann	69

Choudhry, Azhar	84	Dennis, Donn M.	77
Christine, Mazzucco	69	Denton, Wayne H.	70
Chronos, Lambros	75	Derbyshire, Katherine L.	77
Citrome, Leslie	17, 20, 74	de Somer, Marc	84
Clain, Alisabet	87	Detka, Jan	71
Clark, Crystal	47, 80	Detke, Michael	30, 37, 76
Clarke, Diana E.	33, 78	Dhossche, Dirk M.	29
Clayton, Anita	75	DiMuzio, Jennifer	89
Clayton, Anita H.	85	DiPetrillo, Lauren E.	75, 91
Coffey, Barbara	73	Dirks, Bryan L.	17
Cohen, Dan	78, 89	Dodd, Seetal	71
Cohen, Lee S.	34, 91	Dragheim, Marianne	76, 85, 87
Compton, Michael T.	66	Drevets, Wayne	69
Corey, Lisa	91	Du, Yangchun	49, 84, 91
Correll, Christoph	17, 19, 20, 25, 39,	Duca, Anna R.	90
	66, 89	Duda, Weronika	75
Cortese, Bernadette M.	74	Duffy, Farifteh	78
Cosgrove, Victoria E.	61, 71, 83	Duffy, Ruth	89
Courbay, Zane	42	Duhoux, Stephanie	26, 70
Craighead, W. Edward	72	Durgam, Suresh	72, 78, 89
Crismon, M. Lynn	89	Dvergsten, Chris	69
Cross, Alan	36, 69	Edwards, Emmeline	30, 45
Cucchiario, Josephine	71, 72, 78, 89, 90	Efros, Mitchell	73
Cunningham, Jacobi I.	85	Ehrhardt, John D.	84
Curzytek, Katarzyna	75	Ehrich, Elliot	84, 91
Cutler, Andrew J.	69, 74, 81, 89	Ellingrod, Vicki L.	70
Daly, Ella	69	English, Brett A.	88
Daniel, David	84	Eramo, Anna	78, 79, 89, 90
Datto, Catherine	71, 82, 83	Ereshefsky, Larry	76, 88
Davidson, Richard J.	31	Escher, Tobie	74
Davis, Alan T.	81	Evins, Eden	17
Davis, Heather L.	31	Eyerman, David	85
Davis, Lori	16, 19, 25, 33	Falk, Daniel E.	81
Davis, Michael	26, 49	Faraone, Stephen V.	70, 82
Davis, Vicki G.	73, 90	Farchione, Tiffany	17, 19, 25, 50
Deal, Linda	77	Farr, Gaston	69
Dean, Reginald L.	85	Faucett, James	73
Deaver, Daniel	85	Fava, Maurizio	16, 17, 20, 50, 58,
Debelle, Marc	78		66, 73, 75, 76, 84,
DeBoer, Peter	69		87
DeBonis, Dan	81	Feeley, Louisa	83
Deckersbach, Thilo	17	Feinberg, Leah	88
DeGeorge, Pamela	90	Felger, Jennifer	26, 85
Deligiannidis, Kristina	20, 49	Ferguson, Margaret B.	86
Dellva, Mary Anne	86	Ferreira-Cornwell, M.	88
Delong, Liz	45	Fertig, Joanne B.	81
De Luca, Vincenzo	83	Fiedorowicz, Jess G.	46
DeMartinis, Nicholas	84	Fischer, E. Grace	71



Fleischhacker, W.	78	Greenberg, William M.	74
Flynn, Martina J.	73	Greist, John	18
Fochtman, Laura	78	Grigoriadis, Sophie	6
Francis, Andrew	29	Grosser, Bernard	69
Frank, Ellen	61, 72	Grubb, ElizaBeth	84
Freeman, Marlene	16, 20, 34, 48, 73	Guevara, Sara	87
Friedman, Edward S.	37	Guloksuz, Sinan	90
Fried, Ronna	70, 88	Haass-Koffler, Carolina	70
Frye, Mark A.	76	Haig, George	92
Fu, Dong-Jing	90	Halstead, Scott	73
Furmaga, Kevin M.	81	Hameed, Ahmad	77, 88
Furtak, Stephannie L.	88	Hanina, Adam	39
Gabbay, Vilma	73, 75, 86	Hanna, Amira	86
Gale, Phillip D.	81	Hanover, Rita	69, 81
Gao, Keming	72, 85	Hansel, Tonya C.	86
Gao, Linda	71, 79, 91	Haroon, Ebrahim	85
Garabedian, Cathy	91	Harper, Linda	84, 86
Gardner, Kathryn	82	Harris, Herbert	82
Garneau-Fournier, Jade	83	Harris, Margret S. H.	78
Garrett, Amy	83	Harrison, John E.	75
Garzio, Lori M.	91	Harvey, Philip	90, 91
Gasior, Maria	77, 88	Hassan, Mariam	83
Gastfriend, David	70	Hassman, Howard	76
Gaynes, Bradley	17, 48	Heal, David	77, 86
Geibel, Brooke	30	Heemskerk, Jill	52
Gelenberg, Alan	20, 45, 71, 77, 88	Hegarty, Jani	83
Gelovich, Mary	76	Heidi, De Smedt	69
George, Gibson T.	88	Henry, Michael E.	85
George, Sanju	76	Herman, Barry	77
Gerretsen, Philip	26, 79	Hernandez, David	78
Gertsik, Lev	88	Hernandez, Mariely	82
Gibbons, Robert	61, 73	Hernandez-Diaz, Sonia	34, 91
Gift, Thomas	81	Hert, Marc De	79
Gilman, Stephen	87	Hertel, Peter	89
Glick, Ira	20, 77, 88	Hildebrandt, Tom	70
Gliddon, Emma	71	Hill, Lauren	15, 19, 25
Goff, Donald C.	51, 66	Hillefors, Mi	66
Goldberger, Celine	86	Hilsabeck, Robin C.	84
Goldberg, Joseph	20, 33, 44, 51, 82	Hipolito, Moria	92
Goldman, Robert	89, 91	Hosford, David	36, 69
Golembiowska, Krystyna	75	Hough, David	79
Gommoll, Carl	74, 75, 86, 87	Hsu, Jay	89
Goncalves, Vanessa	83	Hsu, Timothy	69, 81
Gosden, J.	77	Hsu, Wei-Chun	82
Grabb, Meg	52, 59	Hu, Chunling	76
Grandison, Lindsey	19, 25	Hudson, James	88
Grandjean, Didier	92	Hummel, Rebecca	84
Grant, Jon E.	77	Hummel, Ruth	84

Huntley, Kristen	30	Kizaki, Miho	89
Hurt, Stephen W.	69	Kocsis, James H.	16
Hutson, Peter	77, 86	Koenig, Aaron	26, 85
Huz, Ilana	87	Korb, Alex	88
Insel, Thomas	9, 11, 56, 57	Kott, Alan	84
Ionescu, Dawn F.	87	Kraemer, Helena	18
Iosifescu, Dan V.	51, 60	Kremer, Charlotte	18
Iovieno, Nadia	72	Kroger, Hans	71, 72
Jacobsen, Paula L.	75, 85, 86	Krone, Beth	70
Jaffe, Richard	88	Kronstein, Phillip	14, 68
Jansen, Joshua F.	86	Krupitsky, Evgeny	70
Jett, John	69	Krystal, Andrew	90
Jha, Amishi	30	Kubera, Marta	71, 74, 75
Jin, Na	89	Kulkarni, Rajiv	86
Johnson, Amy R.	75, 86	Kupfer, David	16, 18, 52, 57, 72
Johnson, Ann E.	81	Kurek, Anna	71
Johnson, Brian R.	90	Kwiatkowski, Molly	91
Johnson, Joe	81	Laezza, Fernanda	82
Johnson, Michael	87	Lally, Niall	75
Jones, Warren	59	Landsberg, Wally	79
Joseph, Melissa	69	Lane, Rosanne	69
Joshi, Gagan	88	LaPorte, Scott	71, 82, 83
Joyce, Mark	84	Lason, Wladyslaw	75
Kamiya, Toshikazu	89	Laszlovszky, István	72, 78, 89
Kane, John	20, 39, 46, 66, 67, 78	Lauder, Sue	71
Kapczinski, Flavio	46	Laughren, Thomas	16, 18, 51, 67
Kasula, Varun	76	Lavigne, Kimberly M.	86
Keefe, Richard	18, 73, 90	Lawson, William B.	92
Kemp, David	38, 46	Leggio, Lorenzo	70
Kenna, George	70	Leigh-Pemberton, Richard	75, 84
Kennedy, James	83	Lemon, Elizabeth	91
Kennedy, Patrick	10, 56	Leppink, Eric	77
Kent, Justine	35, 69	Leśkiewicz, Monika	71, 74, 75
Keshavan, Matcheri S.	78	Leslie, Kimberly R.	74
Ketter, Terence	18, 33, 37, 59, 72, 82, 83	Levenson, Jessica C.	72
Kezic, Iva	69	Li, Huafang	79, 89
Khan, Anzalee	71, 79, 91	Li, Sherrie	83
Khan, Arif	20, 36, 37, 73, 86, 87	Li, Zhihao	85
Khin, Ni	7, 14, 43, 68	Liebowitz, Michael	35, 47, 60, 69, 81
Kim, Sanghyeon	79	Lim, Kelvin O.	30
Kim, Seonghwan	76	Lindenmayer, Jean-Pierre	79, 90
Kim, Sungman	76	Ling, Walter	70
King, Bryan H.	59	Lippiello, Patrick	69
Kinon, Bruce	16, 19	Litman, Robert E.	72
Kishimoto, Taishiro	46	Litten, Raye	16, 31
		Litten, Raye Z.	32, 38, 81
		Locatelli, Allison	89

Loebel, Antony	71, 72, 78, 79, 82, 83, 89, 90, 91	Millet, Robert	76
Loewy, Rachel	67	Mischoulon, David	73, 87
Loft, Henrik	76	Miskowiak, Kamilla	26
Lombard, Jay	82	Miskowiakm, Kamilla	48
Lophaven, Søren N.	75	Mitchell, Michael	77, 88
Loskie, Eileen	77	Mohammad, Othman	72
Lucic, Luka	71, 91	Molpus, Robert	84
Luckenbaugh, David	75, 87	Monti, Louis	69
Lu, Kaifeng	72, 78, 89	Montoya, Ivan	19
Mackin, Scott	50	Mościcki, Eve K.	34, 78
Maes, Michael	75	Mullen, Jamie	83
Mahableshwarkar, Atul R.	75, 76, 85, 86	Murphy, Shannon	91
Mahalchick, Lucy	78	Murrough, James W.	60
Ma, Kaizong	71	Muse, Nina J.	89
Malhotra, Anil	16, 18	Musunuri, Padmapriya	88
Maneru, Cristina	83	Nagy, Krisztián	72, 89
Manji, Husseini	8, 15, 16, 55, 56	Nakajima, Shinichiro	26
Mao, Lian	80	Nakamura, Richard	13, 57
Mao, Yongcai	78	Nakazaki, Eri	89
Marangell, Lauren B.	86	Narasimhan, Meera	90
Marc, Ceusters	69	Narrow, William	33, 34, 78
Marchant, Barrie K.	81	Nasrallah, Henry A.	89
Marder, Steve	16, 18	Nations, Kari	84
Marshall, Kay	81	Neill, Joanna C.	81
Marshall, Randall D.	60, 69, 75, 84	Nelson, Craig	18, 50
Martinez, James M.	86	Nenov, Miroslav	82
Masand, Prakash	76	Newcomer, John	20, 71, 90
Mathew, Sanjay	60, 76, 87	Newcorn, Jeffrey	70
Mathews, Maju	74, 75, 86, 87	Nguyen, Theresa	72
Mattes, Jeffrey	77	Niciu, Mark	26, 87
Matthews, Mark	61	Nicol, Ginger E.	71
Mattingly, Gregory	79	Nielsen, Rebecca Z.	87
Matyas, Gary R.	31	Nierenberg, Andrew	16, 37, 67
Mavissakalian, Matig	47	Nimgaonkar, Vishwajit	78
McCracken, James T.	59	Nolan, Neal	87
McElroy, Susan	58, 77, 88	Norquist, Grayson	67
McEvoy, Joseph P.	47	Nueten, Luc Van	69
McGlade, Erin	89	Nugent, Allison C.	75
McInerney, Kathryn	91	Nugter, Annet	78
McKinney, Anthony	69	Nunez, Rene	74, 75, 86, 87
McQuade, Robert D.	89, 90	Nylander, Anna-Greta	89, 90
Memisoglu, Asli	70, 75, 84	O'Brien, Catherine	69, 81
Menosky, Angela	84	O'Connor, Joann	74
Merritt-Davis, Orlena	74	Odlaug, Brian L.	77
Meyer, Roger E.	77, 88	Olsen, Christina Kurre	75
Michelson, David	16	O'Malley, Stephanie	16
Miller, Andrew H.	85	Ondrus, Matej	77
		O'Neill, James	78

Opler, Mark	71, 79, 91	Quirk, Michael	76
Oshibuchi, Hidehiro	26	Rabinowitz, Jonathan	30, 35
Osimo, Niki	88	Radewonuk, Jana	88
Oslin, David	38	Rajagopalan, Krithika	82, 83, 90
Osman, Doug	91	Raju, Karishma	71
Osser, David	72	Rapaport, Mark H.	15, 17, 19, 20, 25
Othman, Ahmed A.	92	Rapoport, Stanley	71
Paige, Staudenmaier	83	Rappaport, Bob A.	17
Paik, Jong-Woo	76	Rauh, Philip	84
Palfi, Sandor	83	Regulska, Magdalena	75
Palmese, Laura	90	Reilly, James L.	78
Palo, William	85	Reimherr, Frederick W.	81
Pangallo, Beth A.	86	Reimherr, Kathleen	81
Panova-Elektronova, Neli	82	Rele, Shilpa	76
Papakostas, George I.	59, 72, 85, 87	Remington, Gary	91
Parkinson, Amy	83	Ressler, Kerry	72
Pathak, Sanjeev	76, 87	Reutenauer, Erin	90
Patkar, Ashwin	76	Reynolds, Charles F.	85
Patterson, Thomas L.	90	Richards, Erica M.	87
Pearlstein, Jennifer	83	Riesenberg, Robert	87
Pedraza, Juan D.	70	Rishton, Melanie	77
Pendergrass, J. Cara	84	Risinger, Robert	91
Perez-Rodriguez, M.	26, 49	Robieson, Weining	92
Perry, Pamela P.	90	Rodriguez, Stephen	78, 80
Persson, Jennie K.	77	Rogers, James A.	89
Petersen, Timothy	60	Romano, Steve	17, 18
Peterson, Loretta D.	92	Rorick-Kehn, Linda	82
Peters-Strickland, Timothy	49, 78, 89, 90	Rose, Andrew C.	81
Petrakis, Ismene L.	38	Rosenbaum, Jerrold	18
Petrides, Georgios	29	Rosenberg, Leon I.	76
Phillips, Debra	78, 79	Rothman, Brian	71, 79, 91
Phillips, Katharine	18, 19, 25	Rowley, Helen L.	86
Pikalov, Andrei	33, 71, 78, 79, 82, 83, 89, 90	Roybal, Donna	26, 83
Pilar, Lim	69	Rubin, Jonathan	35
Piser, Tim	76	Rubin, Robert A.	85
Plovnick, Robert M.	78	Runion, Jennifer	74
Pooley, James	73	Ruse, Stacy	90
Popescu, Marlene	77	Rush, A. John	5, 25
Popp, Danielle	91	Ruth, Adam	74
Posener, Joel	76	Ruvuna, Francis	74
Pothier, David D.	79	Ryan, Megan L.	81
Potter, William	16, 52	Ryan, Neil	18
Prasad, Konasale M.	78	Ryan, Patrick	79
Price, Blair	76	Sachs, Gary S.	81, 83
Priest, Jacob B.	70	Sahoo, Saddichha	50
Prisciandaro, James J.	84	Sajatovic, Martha	18
Prow, M.	77	Salman, Ester	81
		Saltz, Bruce	18

Sanacora, Gerard	60, 66, 76, 87	Stankovic, Srdjan R.	91
Sanchez, Raymond	78, 90	Starr, H. Lynn	80
Sarampote, Chris	52	Staudenmaier, Paige	83
Sarma, Kaushik	71, 72	Steans, Tammy A.	81
Saunders, Erika	71	Stein, Mark	70
Savitz, Jonathan	46	Stevenson, James M.	78
Scahill, Lawrence	59	Stoltz, Randall R.	91
Schaefer, Eric	71	Stout, Robert L.	32
Schneider, Lon S.	65	Strachan, Martha	74
Schooler, Nina R.	17, 19, 25, 39, 46, 47, 67, 90	Stroescu, Ioan	73
Schronen, Juan	87	Su, Hong-Lin	76, 87
Schulz, Kurt	70	Suppes, Trisha	71
Schweiger, Julia A.	71	Surman, Craig	70
Scott, Rachel	82	Sutor, Shari	76
Sears, Peter	74	Swartz, Holly	15, 19, 25, 61, 72
Sedway, Jan	83	Sweeney, John A.	78
Segreti, Anthony	69	Swift, Robert	70
Serenko, Michael	86	Tandon, Rajiv	78
Shafer, Alan	89	Tanenbaum, Russell	84
Shavkunov, Alexander	82	Tang, Xiongwen	74
Shay, Michelle	71, 82	Targum, Steven D.	36, 50, 84
Shelton, Richard	18, 51, 76, 85	Tarko, Laura	70, 82, 88
Shen, Yifeng	79, 89	Taub, Floyd	85
Shiromani, Priyattam	74	Tauscher-Wisniewski, Sitra	66
Shurtleff, David	30	Tek, Cenk	90
Silk, Jennifer	61	Thase, Michael	15, 17, 20, 44, 51, 75, 76
Silva, Robert	71, 72	Thurmond, Linda M.	85
Silverman, Bernard L.	70, 84, 91	Tiwari, Arun K.	83
Simeonova, Diana	26, 72	Tocco, Michael	79
Simon, Greg	45, 67	Todtenkopf, Mark S.	85
Simonson, Richard B.	90	Tohen, Mauricio	37
Simpson, Tracy	38	Toler, Steven	69
Singareddy, Ravi	74	Tolliver, Bryan	84
Singh, Jaskaran	35, 60, 69	Tomlinson, Anneka	48, 81
Siu, Cynthia	82, 83, 91	Traeger, Lara	87
Skolnick, Phil	11, 17, 31, 57	Trinh, Nhi-Ha	26, 87
Slusarczyk, Joanna	74, 75	Trivedi, Madhukar	46, 75, 76
Smart, LeAnn D.	73, 81	Tsai, Lan-Feng	78, 79, 90
Smit, Andries	78	Tulin, Steven	92
Smith, Katie	85	Turkoz, Ibrahim	90
Smith, Purvi K.	83	Turncliff, Ryan	75
Smith, Robert C.	80	Tye, Susannah J.	76
Sofuoglu, Mehmet	81	Uhde, Thomas W.	74
Sorensen, Per	32	Valjakka, Risto	77
Spencer, Thomas	70	Vallejo, Ana I.	75, 86
Spyker, Daniel A.	80, 91	Vanover, Kimberly E.	36
Stang, Paul	79	Varghese, Sajoy P.	74

Ventura, Joseph	91	Williams, Janet	19, 30, 77, 91
Viguera, Adele C.	91	Winchell, Celia	7, 14, 43, 68
Vijapura, Sagar A.	87	Wirth, Robert	77
Vincent, John B.	83	Witkiewitz, Katie	32
Vitiello, Ben	17, 19, 67	Woods, Sarah B.	70
Volk, Stephen	78	Wood, Terri	84
Vornov, James	76	Woolwine, Bobbi	85
Voss, Erica	79	Wozniak, Janet	82, 88
Wagner, Ann	59	Wright, Jason	71, 82
Wagner, Karen	19, 20	Wright, Suzin M.	85
Walker, Adam	76	Wu, Allen	78
Walker, Rosemary	72	Xu, Jane	79
Walling, David P.	90	Yaroslavsky, Yury	74
Wang, Chao	76	Yeung, Albert	87
Wang, Dana	72	Yeung, Paul P.	80, 91
Wang, Yao	89	Yingling, Michael D.	71
Warnock, Julia "Jill" K.	80	Yonkers, Kimberly	19, 81
Warren, Kenneth	12, 57	Youngstrom, Eric A.	77, 88
Watabe, Kei	82, 90	Yurgelun-Todd, Deborah	89
Waye, Mary	91	Zai, Clement	26, 83
Weber, Wendy	45	Zai, Gwyneth	26, 48
Weiden, Peter J.	45	Zajecka, John	87
Weingard, Kerri	73	Zarate, Carlos	15, 17, 19, 35, 66, 75, 87
Welsh-Bohmer, Kathleen	65	Zimmerman, Mark	73, 88
Wender, Paul H.	81	Zisook, Sidney	20, 88
Wesnes, Keith	65, 76	Zukin, Stephen	74, 78
White, Amanda M.	77, 88	Zummo, Jacqueline	70, 91
White, Stuart F.	70	Zumpano, Laura	84
Wilens, Timothy	35, 69, 81		





**Save the Date:**  
**2015 ASCP Annual Meeting**  
**June 22-25, 2015**  
**Miami Beach, Florida**



**ASCP**  
AMERICAN SOCIETY OF  
CLINICAL PSYCHOPHARMACOLOGY  
[www.ascpp.org](http://www.ascpp.org)

ASCP Executive Office  
5034A Thoroughbred Lane  
Brentwood, Tennessee 37027

phone: 615-649-3085  
fax: 888-417-3311  
email: [info@ascpp.org](mailto:info@ascpp.org)